<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68447</article-id><article-id pub-id-type="doi">10.7554/eLife.68447</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-231818"><name><surname>Toft</surname><given-names>Nicolai J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231819"><name><surname>Axelsen</surname><given-names>Trine V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231820"><name><surname>Pedersen</surname><given-names>Helene L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231821"><name><surname>Mele</surname><given-names>Marco</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8156-7804</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231822"><name><surname>Burton</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231823"><name><surname>Balling</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231824"><name><surname>Johansen</surname><given-names>Tonje</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231826"><name><surname>Thomassen</surname><given-names>Mads</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-231825"><name><surname>Christiansen</surname><given-names>Peer M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-181974"><name><surname>Boedtkjer</surname><given-names>Ebbe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5078-9279</contrib-id><email>eb@biomed.au.dk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Biomedicine, Aarhus University</institution><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, Regionshospitalet Randers</institution><addr-line><named-content content-type="city">Randers</named-content></addr-line><country>Denmark</country></aff><aff id="aff3"><label>3</label><institution>Department of Surgery, Regionshospitalet Randers</institution><addr-line><named-content content-type="city">Randers</named-content></addr-line><country>Denmark</country></aff><aff id="aff4"><label>4</label><institution>Department of Clinical Genetics, University of Southern Denmark</institution><addr-line><named-content content-type="city">Odense</named-content></addr-line><country>Denmark</country></aff><aff id="aff5"><label>5</label><institution>Clinical Genome Center, University and Region of Southern Denmark</institution><addr-line><named-content content-type="city">Odense</named-content></addr-line><country>Denmark</country></aff><aff id="aff6"><label>6</label><institution>Department of Plastic and Breast Surgery, Department of Clinical Medicine, Aarhus University Hospital</institution><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Senior Editor</role><aff><institution>The Wistar Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>05</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68447</elocation-id><history><date date-type="received" iso-8601-date="2021-03-16"><day>16</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-07-02"><day>02</day><month>07</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Toft et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Toft et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68447-v2.pdf"/><abstract><p>Breast cancer heterogeneity in histology and molecular subtype influences metabolic and proliferative activity and hence the acid load on cancer cells. We hypothesized that acid-base transporters and intracellular pH (pH<sub>i</sub>) dynamics contribute inter-individual variability in breast cancer aggressiveness and prognosis. We show that Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport and Na<sup>+</sup>/H<sup>+</sup> exchange dominate cellular net acid extrusion in human breast carcinomas. Na<sup>+</sup>/H<sup>+</sup> exchange elevates pH<sub>i</sub> preferentially in estrogen receptor-negative breast carcinomas, whereas Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport raises pH<sub>i</sub> more in invasive lobular than ductal breast carcinomas and in higher malignancy grade breast cancer. HER2-positive breast carcinomas have elevated protein expression of Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1/SLC9A1 and Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporter NBCn1/SLC4A7. Increased dependency on Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport associates with severe breast cancer: enlarged CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent rises in pH<sub>i</sub> predict accelerated cell proliferation, whereas enhanced CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent net acid extrusion, elevated NBCn1 protein expression, and reduced NHE1 protein expression predict lymph node metastasis. Accordingly, we observe reduced survival for patients suffering from luminal A or basal-like/triple-negative breast cancer with high <italic>SLC4A7</italic> and/or low <italic>SLC9A1</italic> mRNA expression. We conclude that the molecular mechanisms of acid-base regulation depend on clinicopathological characteristics of breast cancer patients. NBCn1 expression and dependency on Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport for pH<sub>i</sub> regulation, measured in biopsies of human primary breast carcinomas, independently predict proliferative activity, lymph node metastasis, and patient survival.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>acid-base</kwd><kwd>luminal A breast cancer</kwd><kwd>metastasis</kwd><kwd>microenvironment</kwd><kwd>proliferation</kwd><kwd>triple-negative breast cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008392</institution-id><institution>Sundhed og Sygdom, Det Frie Forskningsråd</institution></institution-wrap></funding-source><award-id>7025-00050B</award-id><principal-award-recipient><name><surname>Boedtkjer</surname><given-names>Ebbe</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF18OC0053037</award-id><principal-award-recipient><name><surname>Boedtkjer</surname><given-names>Ebbe</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008363</institution-id><institution>Danish Cancer Society</institution></institution-wrap></funding-source><award-id>R136-A8670</award-id><principal-award-recipient><name><surname>Toft</surname><given-names>Nicolai J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Cellular acidity, capacity for net acid extrusion, and expression of acid-base transporters in human breast carcinomas independently predict variation in proliferative activity, lymph node metastasis, and patient survival.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer heterogeneity is a challenge in clinical practice and calls for extensive patient stratification. Similarly, the underlying tumor biology needs evaluation in stratified patient populations. Breast cancers classify into five molecular subtypes (normal-like, luminal A and B, HER2-enriched, basal-like) that differ in metabolic and proliferative activity, metastatic potential, therapeutic responsiveness, and prognosis (<xref ref-type="bibr" rid="bib24">Dai et al., 2015</xref>). Whereas radical surgery can cure most patients with localized breast cancer, disseminated disease requires additional systemic therapy. Available successful therapies target the receptor tyrosine-protein kinase HER2 (ErbB2/neu) and estrogen receptors. However, patients with basal-like/triple-negative breast cancer lack targeted treatment options and currently receive classical chemotherapy (e.g., anthracycline and taxane in combination) with considerable adverse effects (<xref ref-type="bibr" rid="bib4">Ávalos-Moreno et al., 2020</xref>).</p><p>Accelerated intermediary metabolism in breast cancer tissue (<xref ref-type="bibr" rid="bib80">Voss et al., 2020</xref>) burdens the molecular pathways for acidic waste product elimination. In solid cancer tissue, extracellular pH (pH<sub>o</sub>) can reach as low as 6.5 (<xref ref-type="bibr" rid="bib80">Voss et al., 2020</xref>; <xref ref-type="bibr" rid="bib79">Vaupel et al., 1989</xref>), which is distinct from corresponding normal tissue with pH<sub>o</sub> around 7.3–7.4. The acidity of the extracellular tumor microenvironment challenges intracellular pH (pH<sub>i</sub>) homeostasis as it inhibits cellular net acid extrusion (<xref ref-type="bibr" rid="bib17">Bonde and Boedtkjer, 2017</xref>). The changes in metabolic profile and proliferative rate of cancer cells contribute to the acidity of the tumor microenvironment, are important determinants of the malignant phenotype, and shape breast cancer progression (<xref ref-type="bibr" rid="bib50">Parks et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Persi et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Boedtkjer and Pedersen, 2020</xref>).</p><p>Cells generally eliminate their metabolic acid load via membrane proteins that mediate H<sup>+</sup> extrusion (e.g., Na<sup>+</sup>/H<sup>+</sup> exchange, H<sup>+</sup>-ATPase activity) or HCO<sub>3</sub><sup>–</sup> uptake (e.g., Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport) (<xref ref-type="bibr" rid="bib1">Aalkjaer et al., 2014</xref>; <xref ref-type="bibr" rid="bib82">Xu et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Stransky et al., 2016</xref>; see <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Tissue relying partly on fermentative glycolysis can also eliminate acidic waste products from metabolism through coupled transport of H<sup>+</sup> and lactate via monocarboxylate transporters (<xref ref-type="bibr" rid="bib52">Pérez-Escuredo et al., 2016</xref>). In human and murine breast cancer tissue analyzed without stratification by molecular subtype, Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity is elevated and protein expression of the Na<sup>+</sup>,HCO<sub>3</sub><sup>– </sup>cotransporter NBCn1 (SLC4A7) and monocarboxylate transporters MCT1 (SLC16A1) and MCT4 (SLC16A3) are upregulated compared to normal breast tissue (<xref ref-type="bibr" rid="bib12">Boedtkjer, 2019</xref>; <xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>). Protein expression of the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 (SLC9A1) is more variable in primary breast cancer tissue showing unchanged or only moderately elevated levels (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>) when compared to normal breast tissue as one unstratified group.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cellular net acid extrusion in human breast cancer tissue and normal breast tissue relies on extracellular Na<sup>+</sup> and is partially CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent consistent with the expression of Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporter NBCn1 and Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1.</title><p>Moreover, steady-state intracellular pH (pH<sub>i</sub>) and the capacity for net acid extrusion are elevated in human breast cancer tissue compared to normal breast tissue. (<bold>A</bold>) Exemplar fluorescence images of 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF)-loaded organoids freshly isolated from human breast cancer tissue (lower panel) and normal breast tissue (upper panel). The scale bars represent 100 µm. (<bold>B</bold>) Illustration of the experimental procedure for acute enzymatic isolation of organoids from human breast biopsies and a schematic showing the acid-base transporters involved in pH<sub>i</sub> control in breast cancer cells. The image was generated with <ext-link ext-link-type="uri" xlink:href="http://biorender.com/">Biorender.com</ext-link>. CA, carbonic anhydrase. (<bold>C,D</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in human breast cancer tissue (<bold>C</bold>, n=75–76) and normal breast tissue (<bold>D</bold>, n=48–49). The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>E</bold>) Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human breast cancer tissue and normal breast tissue (n=48–76). <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>F</bold>) Initial steady-state pH<sub>i</sub> in human breast cancer tissue (n=79–80) and normal breast tissue (n=49–50) in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>. (<bold>G–I</bold>) Representative immunohistochemical images (<bold>G</bold>) and summarized pathologist-scored protein expression data for NHE1 (<bold>H</bold>, n=79) and NBCn1 (<bold>I</bold>, n=79) in human breast carcinomas. The size bars represent 100 µm. Data in panels E and F were compared by mixed-effects analyses followed by Sidak’s multiple comparisons test. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between breast cancer and normal breast tissue. *p&lt;0.05, ***p&lt;0.001 vs. normal breast tissue under similar conditions. <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> contains the data pertaining to this figure and the de-identified clinicopathological information used to stratify data in <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig4">4</xref>, <xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="fig" rid="fig7">7</xref> and <xref ref-type="fig" rid="fig8">8</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>; this information is combined in the multiple linear and logistic regression analyses illustrated in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data file containing NBCn1 and NHE1 protein expression levels, steady-state intracellular pH (pH<sub>i</sub>) values, and net acid extrusion capacities linked to de-identified clinical and pathological patient characteristics.</title><p>Note that this source data file pertains to <xref ref-type="fig" rid="fig1">Figure 1</xref> but it also contains the clinicopathological information used for stratification in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="fig" rid="fig7">7,</xref> and <xref ref-type="fig" rid="fig8">8</xref>, and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>; for the multiple linear and logistic regression analyses in <xref ref-type="fig" rid="fig6">Figure 6</xref>; and for the plots in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68447-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human breast cancer tissue and normal breast tissue.</title><p>(<bold>A</bold>) Primary breast cancer tissue (n=75–76). (<bold>B</bold>) Normal breast tissue (n=48–49). <xref ref-type="supplementary-material" rid="fig1s1sdata1">Figure 1—figure supplement 1—source data 1</xref> provides the data pertaining to this figure and used for stratification in the figure supplements relating to <xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig4">4</xref>, <xref ref-type="fig" rid="fig5">5</xref>, <xref ref-type="fig" rid="fig7">7,</xref> and <xref ref-type="fig" rid="fig8">8</xref>.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Data file containing net acid extrusion capacities calculated at specified intracellular pH (pH<sub>i</sub>) levels and linked to de-identified clinical and pathological patient characteristics.</title><p>Note that this source data file pertains to <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> but it also contains the clinicopathological information used for stratification in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref> and <xref ref-type="fig" rid="fig2s2">2</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68447-fig1-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Net acid extrusion from cancer cells elevates the cytosolic pH and acidifies the outer cell surface and interstitial space. In various model systems, acid-base transporters can modify carcinogenesis and the behavior of cancer cells including cancer cell proliferation, migration, and invasion (<xref ref-type="bibr" rid="bib16">Boedtkjer and Pedersen, 2020</xref>; <xref ref-type="bibr" rid="bib3">Amith and Fliegel, 2017</xref>; <xref ref-type="bibr" rid="bib71">Stock and Pedersen, 2017</xref>). Although detailed molecular mechanisms are not yet established, elevated pH<sub>i</sub> maintains metabolic activity (<xref ref-type="bibr" rid="bib49">Parks et al., 2013</xref>), increases DNA and protein synthesis (<xref ref-type="bibr" rid="bib51">Pedersen, 2006</xref>), and accelerates cell cycle progression (<xref ref-type="bibr" rid="bib27">Flinck et al., 2018</xref>) in cultured cell lines. In accordance, mice with disrupted expression of NBCn1 show delayed tumor development and decelerated tumor growth when tested using models of carcinogen- and ErbB2-induced breast cancer (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>).</p><p>Acidification at the outer cell surface depends on the rate of net acid transfer across the cell membrane and on diffusion hindrances that limit exchange with the bulk interstitial solution and the blood stream. Cell surface pH can modify cell-cell and cell-matrix interactions (<xref ref-type="bibr" rid="bib69">Stock et al., 2005</xref>; <xref ref-type="bibr" rid="bib58">Riemann et al., 2019</xref>), pH gradients from the leading to the rear end of cells can promote directional migration (<xref ref-type="bibr" rid="bib70">Stock et al., 2007</xref>; <xref ref-type="bibr" rid="bib11">Boedtkjer et al., 2016</xref>), and interstitial acidification of the tumor microenvironment has potential for modifying anti-cancer immune responses (<xref ref-type="bibr" rid="bib20">Cassim and Pouyssegur, 2019</xref>). Indeed, cancer progression through metastasis and development of treatment resistance have been reported sensitive to inhibition of Na<sup>+</sup>/H<sup>+</sup> exchangers (<xref ref-type="bibr" rid="bib3">Amith and Fliegel, 2017</xref>; <xref ref-type="bibr" rid="bib71">Stock and Pedersen, 2017</xref>); however, several anti-cancer effects of pharmacologically inhibiting Na<sup>+</sup>/H<sup>+</sup> exchange appear only partly pH-dependent (<xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Loo et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Schwab et al., 2012</xref>) and can be caused by NHE1-independent toxicity due to intracellular drug accumulation (<xref ref-type="bibr" rid="bib60">Rolver et al., 2020</xref>).</p><p>Despite the molecular and mechanistic insights from human cultured cell lines and inbred mouse models, the consequences of pH deregulation in human cancer tissue remain unclear. In particular, mechanisms of pH control in breast cancer tissue and their consequences for disease progression were previously explored in models that do not reflect the heterogeneity of human breast cancer. In the current study, we investigated an extensive cohort of human breast cancer patients, sufficiently large to reflect the heterogeneity of acid-base conditions and the variation in cellular handling of metabolic waste products. We tested the hypotheses that (a) specific clinical and pathological characteristics accelerate cellular net acid extrusion and determine the underlying molecular mechanisms of pH regulation in human breast cancer tissue; and (b) the capacity for cellular net acid extrusion, the steady-state pH<sub>i</sub> level, and the expression of acid-base transporters in human breast cancer tissue predict the severity of disease.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>We sampled human tissue biopsies from an extensive cohort of 110 women with breast cancer (<xref ref-type="table" rid="table1">Table 1</xref>) and evaluated pH<sub>i</sub> dynamics based on organoids freshly isolated from the breast cancer tissue and corresponding normal breast tissue (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Within this patient population, we stratified the pH<sub>i</sub> dynamics and the NHE1 and NBCn1 expression levels by histopathology (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), malignancy grade (<xref ref-type="fig" rid="fig3">Figure 3</xref>), estrogen receptor status (<xref ref-type="fig" rid="fig4">Figure 4</xref>), and HER2 status (<xref ref-type="fig" rid="fig5">Figure 5</xref>); and adjusted for variation in other clinical and pathological characteristics (<xref ref-type="fig" rid="fig6">Figure 6</xref>). We then explored how the pH<sub>i</sub> dynamics and the NHE1 and NBCn1 protein expression levels relate to cancer cell proliferation (<xref ref-type="fig" rid="fig7">Figure 7</xref>) and lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Finally, we evaluated how variation in expression levels for acid-base transporters influence patient survival within individual breast cancer molecular subtypes (<xref ref-type="fig" rid="fig9">Figures 9</xref> and <xref ref-type="fig" rid="fig10">10</xref>, and <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplements 1</xref> and <xref ref-type="fig" rid="fig10s2">2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport is critical for cellular net acid extrusion and steady-state intracellular pH (pH<sub>i</sub>) in human invasive ductal and, particularly, lobular breast carcinomas.</title><p>(<bold>A,B</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in human invasive lobular (<bold>A</bold>, n=8–9) and ductal (<bold>B</bold>, n=60–62) breast carcinomas. The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>C</bold>) Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human invasive lobular and ductal breast carcinomas (n=8–62). <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in human invasive lobular (n=9) and ductal (n=64–65) breast carcinomas in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>. Data in panels C and D were compared by mixed-effects analyses. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between human invasive lobular and ductal breast carcinomas. (<bold>E,F</bold>) Summarized pathologist-scored, immunohistochemistry-based protein expression data for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in human invasive lobular (n=8) and ductal (n=65) breast carcinomas. Protein expression in human invasive lobular and ductal breast carcinomas was compared by χ<sup>2</sup> tests for trend. <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> provides data from mucinous adenocarcinomas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Na<sup>+</sup>/H<sup>+</sup> exchange and Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity regulate intracellular pH (pH<sub>i</sub>) in mucinous adenocarcinomas.</title><p>(<bold>A</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in human mucinous adenocarcinomas (n=5). The time scale within the dotted rectangle is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>B,C</bold>) Cellular net acid extrusion activities in human mucinous adenocarcinomas plotted as functions of pH<sub>i</sub> (<bold>B</bold>) and calculated for the pH<sub>i</sub> range 6.5–6.6 (<bold>C</bold>) in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (n=5). (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in human mucinous adenocarcinomas (n=5) in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human invasive lobular and ductal breast carcinomas.</title><p>(<bold>A</bold>) Invasive lobular primary breast carcinomas (n=8–9). (<bold>B</bold>) Invasive ductal primary breast carcinomas (n=60–62).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig2-figsupp2-v2.tif"/></fig></fig-group><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Steady-state intracellular pH (pH<sub>i</sub>) is elevated in human breast carcinomas of high malignancy grade due to cellular CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent net acid extrusion.</title><p>(<bold>A–C</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in human invasive ductal breast carcinomas of malignancy grades I (<bold>A</bold>, n=12–14), II (<bold>B</bold>, n=34), and III (<bold>C</bold>, n=14). The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>D</bold>) Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human invasive ductal breast carcinomas of malignancy grades I, II, and III (n=12–34). <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>E</bold>) Initial steady-state pH<sub>i</sub> in human invasive ductal breast carcinomas of malignancy grades I (n=14–15), II (n=35), and III (n=15) in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>. Data in panels D and E were compared by mixed-effects analyses and repeated-measures one-way ANOVA with post-test for linear trend. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between human breast carcinomas of malignancy grades I, II, and III. (<bold>F, G</bold>) Summarized pathologist-scored, immunohistochemistry-based protein expression data for NHE1 (<bold>F</bold>, n=65) and NBCn1 (<bold>G</bold>, n=65) in human invasive ductal carcinomas stratified by malignancy grade. Protein expression in human breast carcinomas of malignancy grades I, II, and III was compared by χ<sup>2</sup> tests.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human invasive ductal breast carcinomas of malignancy grades I, II, and III.</title><p>(<bold>A</bold>) Primary breast carcinomas of malignancy grade I (n=12–14). (<bold>B</bold>) Primary breast carcinomas of malignancy grade II (n=34). (<bold>C</bold>) Primary breast carcinomas of malignancy grade III (n=14).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig3-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Intracellular pH (pH<sub>i</sub>) is elevated in estrogen receptor-negative breast cancer.</title><p>(<bold>A,B</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in human breast carcinomas stratified by estrogen receptor status (<bold>A</bold>: negative, n=6; <bold>B</bold>: positive, n=63–64). The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>C</bold>) Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human breast carcinomas stratified by estrogen receptor status (n=6–64). <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in human estrogen receptor-negative (0–15% ER<sup>+</sup>, n=7–8) and -positive (90–100% ER<sup>+</sup>, n=66–67) breast carcinomas. Data in panels C and D were compared by mixed-effects analyses. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between estrogen receptor-negative and -positive breast carcinomas. (<bold>E,F</bold>) Pathologist-scored, immunohistochemistry-based protein expression levels for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in human breast carcinomas (n=73) stratified by estrogen receptor status. Protein expression in human estrogen receptor-negative and -positive breast carcinomas was compared by χ<sup>2</sup> tests for trend.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as function of intracellular pH (pH<sub>i</sub>) for human breast carcinomas stratified by estrogen receptor status.</title><p>(<bold>A</bold>) Estrogen receptor-negative primary breast carcinomas (n=6). (<bold>B</bold>) Estrogen receptor-positive primary breast carcinomas (n=63–64).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig4-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Protein expression of NHE1 and NBCn1 is elevated in HER2-positive human breast cancer.</title><p>(<bold>A,B</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced intracellular pH (pH<sub>i</sub>) dynamics in human HER2-positive (<bold>A</bold>, n=9–11) and HER2-normal (<bold>B</bold>, n=58–61) breast carcinomas. The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>C</bold>) Cellular net acid extrusion activities in the presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human breast carcinomas stratified by HER2 status (n=9–61). <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in HER2-positive (n=10–11) and -normal (n=63) human breast carcinomas. Data in panels C and D were compared by mixed-effects analyses. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between HER2-positive and -normal breast carcinomas. (<bold>E,F</bold>) Summarized pathologist-scored, immunohistochemistry-based protein expression data for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in human breast carcinomas (n=73) stratified by HER2 status. Protein expression in human HER2-positive and -normal breast carcinomas was compared by χ<sup>2</sup> tests for trend.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in the presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human breast carcinomas stratified by HER2 status.</title><p>(<bold>A</bold>) HER2-positive primary breast carcinomas (n=9–11). (<bold>B</bold>) HER2-normal primary breast carcinomas (n=58–61).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig5-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Histology, malignancy grade, and receptor expression profiles are independent predictors of intracellular pH (pH<sub>i</sub>) dynamics and acid-base transporter expression in human invasive lobular and ductal breast carcinomas.</title><p>(<bold>A–D</bold>) Multiple linear regression analyses show the independent influences of patient age, tumor size, histology, malignancy grade, and expression of estrogen and HER2 receptors on steady-state pH<sub>i</sub> and net acid extrusion capacity in human breast cancer tissue (n=78). Data were adjusted for inter-investigator variation. <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> provides plots of steady-state pH<sub>i</sub> and net acid extrusion as functions of tumor size and patient age. (<bold>E,F</bold>) Ordinal logistic regression analyses show the independent influences of patient age, tumor size, histology, malignancy grade, and expression of estrogen and HER2 receptors on protein expression levels for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in human breast cancer tissue (n=73).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Plots of acid-base parameters in human breast cancer tissue (n=64–74) as functions of tumor size (<bold>A,C</bold>) and patient age (<bold>B,D</bold>).</title><p>Statistical relationships among the variables were tested by Spearman’s correlation analyses.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig6-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Steady-state intracellular pH (pH<sub>i</sub>) is elevated in human breast carcinomas with high proliferative activity (elevated Ki67 index).</title><p>(<bold>A,B</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics in breast carcinomas with high (<bold>A</bold>, 35–90% Ki67<sup>+</sup>, n=19–20) and low (<bold>B</bold>, 0–30% Ki67<sup>+</sup>, n=49–51) Ki67 index. The time scale within the dotted rectangles is expanded in order to improve resolution during the pH<sub>i</sub> recovery phase. (<bold>C</bold>) Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> were calculated in the pH<sub>i</sub> range 6.5–6.6 for human breast carcinomas stratified by Ki67 index (n=19–51). <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> provides a detailed analysis of the net acid extrusion capacity as function of pH<sub>i</sub>. (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in breast carcinomas with high (n=20) and low (n=53–54) Ki67 index. Data in panels C and D were compared by mixed-effects analyses. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between breast carcinomas with high and low Ki67 index. (<bold>E,F</bold>) Summarized pathologist-scored, immunohistochemistry-based protein expression levels for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in human breast carcinomas (n=73) stratified by Ki67 index. Protein expression in human breast carcinomas of low and high Ki67 index was compared by χ<sup>2</sup> tests for trend. (<bold>G</bold>) Results of binominal logistic regression analyses where the influence of the acid-base parameters and transporter expression levels on cellular proliferation was adjusted for patient age, tumor size, histology, malignancy grade, estrogen receptor status, HER2 status, and inter-investigator variation (n=73–78). Odds ratios (OR) are given for variables showing statistically significant association.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human breast carcinomas stratified by Ki67 index.</title><p>(<bold>A</bold>) Primary breast carcinomas with high proliferative index (35–90% Ki67<sup>+</sup> cells; n=19–20). (<bold>B</bold>) Primary breast carcinomas with low proliferative index (0–30% Ki67<sup>+</sup> cells; n=49–51).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig7-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Primary breast cancer tissue from patients with axillary lymph node metastases shows higher Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity during intracellular acidification, higher NBCn1 expression, and lower NHE1 expression than breast cancer tissue from patients without metastases.</title><p>(<bold>A,B</bold>) Traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced intracellular pH (pH<sub>i</sub>) dynamics in primary breast carcinomas from patients with (<bold>A</bold>, n=25–28) and without (<bold>B</bold>, n=42–44) axillary lymph node metastases. Time scales within the dotted rectangles are expanded to improve resolution during the pH<sub>i</sub> recovery. (<bold>C</bold>) Cellular net acid extrusion activities in presence and absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> calculated in the pH<sub>i</sub> range 6.5–6.6 for primary breast carcinomas stratified by axillary lymph node status (n=25–44). <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> provides detailed analysis of net acid extrusion capacities as function of pH<sub>i</sub>. (<bold>D</bold>) Initial steady-state pH<sub>i</sub> in primary breast carcinomas from patients with (n=28) and without (n=45–46) lymph node metastases. Data in panels C and D were compared by mixed-effects analyses. ‘Interaction’ reports whether the effect of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> varies between breast carcinomas from patients with and without lymph node metastases. (<bold>E,F</bold>) Summarized pathologist-scored, immunohistochemistry-based protein expression levels for NHE1 (<bold>E</bold>) and NBCn1 (<bold>F</bold>) in primary breast carcinomas from patients with (n=24) and without (n=49) lymph node metastases. Protein expression data were compared by χ<sup>2</sup> tests for trend. (<bold>G</bold>) Results of binominal logistic regression analyses where influences of acid-base parameters and transporter expression levels on lymph node metastasis were adjusted for patient age, tumor size, histology, malignancy grade, estrogen receptor status, HER2 status, and inter-investigator variation (n=73–78). Odds ratios (OR) are given for variables showing statistically significant association.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Cellular net acid extrusion activities in presence and nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> plotted as functions of intracellular pH (pH<sub>i</sub>) for human primary breast carcinomas stratified by axillary lymph node status.</title><p>(<bold>A</bold>) Primary breast carcinomas from patients with lymph node metastases (n=25–28). (<bold>B</bold>) Primary breast carcinomas from patients with no lymph node metastases (n=42–44).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig8-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>The levels of <italic>SLC9A1</italic> mRNA, encoding NHE1, vary among breast cancer subtypes, and high <italic>SLC9A1</italic> expression is associated with improved survival in patients with luminal A breast cancer.</title><p>(<bold>A</bold>) Variation in <italic>SLC9A1</italic> mRNA levels among patients with different breast cancer subtypes (n=135–344). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref> provides data on mRNA expression of <italic>ESR1</italic>, <italic>PGR</italic>, <italic>ERBB2</italic>, <italic>MKI67</italic>, <italic>LDHA</italic>, <italic>PECAM1</italic>, and <italic>CD34</italic> in breast cancer tissue of the different molecular subtypes. <xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref> provides results from correlation analyses between <italic>SLC9A1</italic> mRNA expression and the mRNA levels for <italic>ESR1</italic>, <italic>PGR</italic>, <italic>ERBB2</italic>, <italic>SLC4A7</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic>. *p&lt;0.05, ***p&lt;0.001. (<bold>B–G</bold>) Survival curves stratified by <italic>SLC9A1</italic> mRNA levels in patients with different breast cancer subtypes. The ticks on the curves represent censored subjects. Survival data were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. HR, hazard ratio.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>The mRNA expression for <italic>SLC9A1</italic> correlates with that of <italic>ESR1</italic> and <italic>ERBB2</italic>.</title><p>When adjusted for expression of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>, the mRNA expression of <italic>SLC9A1</italic> does not correlate with that of <italic>SLC4A7</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic> (n=409–1162).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68447-fig9-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Transcript patterns for the different molecular subtypes of breast cancer.</title><p>We observe systematic differences in mRNA levels for estrogen (<bold>A</bold>: <italic>ESR1,</italic> n=135–344), progesterone (<bold>B</bold>: <italic>PGR</italic>, n=162–438), and HER2 (<bold>C</bold>: <italic>ERBB2</italic>, n=162–438) receptors, the proliferative marker Ki67 (<bold>D</bold>: <italic>MKI67</italic>, n=135–344), lactate dehydrogenase (<bold>E</bold>: <italic>LDHA</italic>, n=135–344) involved in fermentative glycolysis, and the angiogenic markers PECAM1/CD31 (<bold>F</bold>: <italic>PECAM1</italic>, n=162–438) and CD34 (<bold>G</bold>: <italic>CD34</italic>, n=162–438).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig9-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>The levels of <italic>SLC4A7</italic> mRNA, encoding NBCn1, vary among breast cancer subtypes, and high SLC4A7 expression is associated with poor survival in patients with luminal A or basal-like breast cancer.</title><p>(<bold>A</bold>) Variation in <italic>SLC4A7</italic> mRNA levels among patients with different breast cancer subtypes (n=135–344). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. *p&lt;0.05, ***p&lt;0.001. <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref> provides results from correlation analyses between <italic>SLC4A7</italic> mRNA expression and the mRNA levels for <italic>ESR1</italic>, <italic>PGR</italic>, <italic>ERBB2</italic>, <italic>SLC9A1</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic>. (<bold>B–G</bold>) Survival curves stratified by <italic>SLC4A7</italic> mRNA levels in patients with different breast cancer molecular subtypes. The ticks on the curves represent censored subjects. Survival data were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. HR, hazard ratio. <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1</xref> provides results on the expression and survival consequences of <italic>SLC16A1</italic> mRNA. <xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2</xref> provides results on the expression and survival consequences of <italic>SLC16A3</italic> mRNA.</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>The mRNA expression for <italic>SLC4A7</italic> correlates with that of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>.</title><p>When adjusted for expression of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>, the mRNA expression of <italic>SLC4A7</italic> does not correlate with that of <italic>SLC9A1</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic> (n=409–1162).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68447-fig10-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig10-v2.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>The levels of <italic>SLC16A1</italic> mRNA, encoding MCT1, vary among breast cancer subtypes but are not associated with significant changes in patient survival.</title><p>(<bold>A</bold>) Variation in <italic>SLC16A1</italic> mRNA levels among patients with different breast cancer subtypes (n=162–438). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. <xref ref-type="supplementary-material" rid="fig10s1sdata1">Figure 10—figure supplement 1—source data 1</xref> provides results from correlation analyses between SLC16A1 mRNA expression and the mRNA levels for ESR1, PGR, ERBB2, <italic>SLC4A7</italic>, SLC9A1, and <italic>SLC16A3</italic> . (<bold>B–G</bold>) Survival curves stratified by <italic>SLC16A1</italic> mRNA levels in patients with different breast cancer subtypes. The ticks on the curves represent censored subjects. Survival data were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. HR, hazard ratio. *p&lt;0.05, ***p&lt;0.001.</p><p><supplementary-material id="fig10s1sdata1"><label>Figure 10—figure supplement 1—source data 1.</label><caption><title>The mRNA expression for <italic>SLC16A1</italic> correlates with that of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>.</title><p>When adjusted for expression of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>, the mRNA expression of <italic>SLC16A1</italic> does not correlate with that of <italic>SLC4A7</italic>, <italic>SLC9A1</italic>, and <italic>SLC16A3</italic> (n=409–1457).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68447-fig10-figsupp1-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig10-figsupp1-v2.tif"/></fig><fig id="fig10s2" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 2.</label><caption><title>The levels of <italic>SLC16A3</italic> mRNA, encoding MCT4, vary among breast cancer subtypes, and high <italic>SLC16A3</italic> expression is associated with poor survival except in luminal A breast cancer.</title><p>(<bold>A</bold>) Variation in <italic>SLC16A3</italic> mRNA levels among patients with different breast cancer subtypes (24–141). Expression data were compared by one-way ANOVA followed by Tukey’s post-test. <xref ref-type="supplementary-material" rid="fig10s2sdata1">Figure 10—figure supplement 2—source data 1</xref> provides results from correlation analyses between SLC16A3 mRNA expression and the mRNA levels for ESR1, PGR, ERBB2, SLC4A7, SLC9A1, and SLC16A1. (<bold>B–G</bold>) Association of <italic>SLC16A3</italic> mRNA expression level with survival in patients with different breast cancer subtypes. The ticks on the curves represent censored subjects. Survival data were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. HR, hazard ratio. *p&lt;0.05, ***p&lt;0.001.</p><p><supplementary-material id="fig10s2sdata1"><label>Figure 10—figure supplement 2—source data 1.</label><caption><title>The mRNA expression for <italic>SLC16A3</italic> correlates with that of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic>.</title><p>When adjusted for expression of <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2, </italic>the mRNA expression of <italic>SLC16A3</italic> does not correlate with that of <italic>SLC4A7</italic>, <italic>SLC9A1</italic>, and <italic>SLC16A1</italic> (n=409).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-68447-fig10-figsupp2-data1-v2.docx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig10-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinical and pathological characteristics of the patient cohort investigated for intracellular pH (pH<sub>i</sub>) dynamics and protein expression.</title></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top">Number of patients</td><td valign="top">110</td></tr><tr><td valign="top">Patient age (years; median, interquartile range)</td><td valign="top">64.5 (56–74)</td></tr><tr><td valign="top">Tumor size (mm; median, interquartile range)</td><td valign="top">18 (14–26)</td></tr><tr><td colspan="2" valign="top">Histological type</td></tr><tr><td valign="top">Invasive ductal carcinomas</td><td valign="top">92 (84%)</td></tr><tr><td valign="top">Invasive lobular carcinomas</td><td valign="top">92 (84%)</td></tr><tr><td valign="top">Mucinous adenocarcinomas</td><td valign="top">5 (5%)</td></tr><tr><td valign="top">Tubular carcinoma</td><td valign="top">2 (2%)</td></tr><tr><td valign="top">Pleomorphic lobular carcinoma</td><td valign="top">1 (1%)</td></tr><tr><td colspan="2" valign="top">HER2 receptor status</td></tr><tr><td valign="top">Normal</td><td valign="top">95 (86%)</td></tr><tr><td valign="top">Overexpression or gene amplification</td><td valign="top">15 (14%)</td></tr><tr><td valign="top">Estrogen receptor status</td><td valign="top"/></tr><tr><td valign="top">90–100% ER<sup>+</sup> cells</td><td valign="top">99 (90%)</td></tr><tr><td valign="top">0–15% ER<sup>+</sup> cells</td><td valign="top">11 (10%)</td></tr><tr><td valign="top">Malignancy grade</td><td valign="top"/></tr><tr><td valign="top">I</td><td valign="top">31 (28%)</td></tr><tr><td valign="top">II</td><td valign="top">52 (47%)</td></tr><tr><td valign="top">III</td><td valign="top">22 (20%)</td></tr><tr><td valign="top">Not graded</td><td valign="top">5 (5%)</td></tr><tr><td valign="top">Axillary lymph node status</td><td valign="top"/></tr><tr><td valign="top">Negative</td><td valign="top">69 (63%)</td></tr><tr><td valign="top">Isolated tumor cells</td><td valign="top">15 (14%)</td></tr><tr><td valign="top">Micro-metastases</td><td valign="top">5 (5%)</td></tr><tr><td valign="top">Macro-metastases</td><td valign="top">21 (19%)</td></tr><tr><td valign="top">Ki67 index</td><td valign="top"/></tr><tr><td valign="top">0–30% Ki67<sup>+</sup> cells</td><td valign="top">82 (75%)</td></tr><tr><td valign="top">35–90% Ki67<sup>+</sup> cells</td><td valign="top">28 (25%)</td></tr></tbody></table></table-wrap><sec id="s2-1"><title>The elevated net acid extrusion capacity is Na<sup>+</sup>- and partly CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent in human breast cancer tissue</title><p>We freshly isolated organoids from human breast biopsies by partial collagenase digestion (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). We prepared the organoids in immediate continuation of the breast-conserving surgery and investigated them directly after isolation without culture in order to avoid phenotypic changes. We previously confirmed that organoids freshly isolated from breast tissue biopsies consist predominantly of cytokeratin-19-positive epithelial cells with few smooth muscle α-actin-positive myofibroblasts (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>).</p><p>We experimentally induced intracellular acidification by NH<sub>4</sub><sup>+</sup>-prepulse technique (<xref ref-type="bibr" rid="bib18">Boron and De Weer, 1976</xref>; <xref ref-type="bibr" rid="bib14">Boedtkjer and Aalkjaer, 2012</xref>) as illustrated in <xref ref-type="fig" rid="fig1">Figure 1C</xref> for breast cancer tissue and <xref ref-type="fig" rid="fig1">Figure 1D</xref> for normal breast tissue. Addition of NH<sub>4</sub>Cl to the experimental bath solution acutely elevates pH<sub>i</sub> as NH<sub>3</sub> traverses plasma membranes and binds H<sup>+</sup> from the cytosol. The subsequent gradual decline of pH<sub>i</sub> occurs when NH<sub>4</sub><sup>+</sup> enters cells—predominantly through plasma membrane K<sup>+</sup> conductances (e.g., K<sup>+</sup> channels and Na<sup>+</sup>/K<sup>+</sup>-ATPases)—and base equivalents are extruded, for instance, through Cl<sup>–</sup>/HCO<sub>3</sub><sup>–</sup> exchange. Washout of NH<sub>4</sub>Cl then causes NH<sub>3</sub> to rapidly leave the cells; and intracellular acidification ensues when H<sup>+</sup>, as a consequence, is liberated from intracellular NH<sub>4</sub><sup>+</sup> and accumulates in the cytosol.</p><p>Assessing the patient population as a whole, we observed that cellular net acid extrusion during intracellular acidification was almost fully dependent on extracellular Na<sup>+</sup> and relied on both CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent and -independent transport mechanisms (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). As schematically illustrated in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, these observations support previous reports (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>) that Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporters and Na<sup>+</sup>/H<sup>+</sup> exchangers are mainly responsible for cellular net acid extrusion in human breast cancer tissue. We observed upregulated capacity for Na<sup>+</sup>/H<sup>+</sup> exchange activity during carcinogenesis based on the faster Na<sup>+</sup>-dependent pH<sub>i</sub> recovery in organoids freshly isolated from breast cancer tissue compared to normal breast tissue when evaluated in the nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>). Likewise, we detected contribution from Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport as the ability to recover pH<sub>i</sub> faster and at more alkaline pH<sub>i</sub> when CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> was present (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>).</p><p>The pH<sub>i</sub> traces (<xref ref-type="fig" rid="fig1">Figure 1C,D</xref>) recorded from freshly processed breast tissue biopsies allowed us to evaluate (a) the initial steady-state pH<sub>i</sub> level with extracted values summarized in <xref ref-type="fig" rid="fig1">Figure 1F</xref> and (b) the capacity for cellular net acid extrusion during pH<sub>i</sub> recovery from NH<sub>4</sub><sup>+</sup>-prepulse-induced acidification (dotted rectangles in <xref ref-type="fig" rid="fig1">Figure 1C,D</xref>) with calculated values summarized in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. As the acid extrusion mechanisms activate at low pH<sub>i</sub> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), their activities must be compared at equivalent pH<sub>i</sub> values: at pH<sub>i </sub>6.5–6.6, we demonstrated a greater capacity for net acid extrusion in human breast cancer tissue compared to normal breast tissue, whether examined in the presence or nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The net acid extrusion capacity in breast cancer tissue was upregulated predominantly in the near-neutral pH<sub>i</sub> range (compare <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>), which was also reflected in an elevated steady-state pH<sub>i</sub> when human breast cancer tissue was investigated under similar experimental conditions as normal breast tissue either with or without CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> present (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The drop in steady-state pH<sub>i</sub> in response to nominal omission of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) supports a greater contribution from Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport compared to anion exchange in the near-physiological pH<sub>i</sub> range (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>In congruence with the functional observations, we identified prominent protein expression of NHE1 and NBCn1 in the human breast cancer tissue and considerable inter-individual variation within the evaluated patient population (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>).</p></sec><sec id="s2-2"><title>Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport is more pronounced in invasive lobular than ductal breast carcinomas</title><p>Breast cancer is histopathologically diverse, but invasive ductal and lobular breast carcinomas are most frequent (<xref ref-type="table" rid="table1">Table 1</xref>). We evaluated whether the mechanisms of net acid extrusion differ between tumors of separate histopathologies (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Invasive lobular (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>) and ductal (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>) breast carcinomas both showed dual dependency on Na<sup>+</sup>/H<sup>+</sup> exchange and Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport for pH<sub>i</sub> regulation. We observed a tendency toward greater relative capacity for net acid extrusion via Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport during intracellular acidification in invasive lobular than ductal breast carcinomas (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). This increased influence of Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport in invasive lobular carcinomas was more pronounced with respect to steady-state pH<sub>i</sub> control where it reached statistical significance both before (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) and after (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) we adjusted for variation in other clinicopathological characteristics (i.e., patient age, tumor size, malignancy grade, estrogen receptor expression, and HER2 status).</p><p>Expression of NHE1 and NBCn1 protein was generally moderate in invasive lobular carcinomas and showed less inter-individual variation than observed for invasive ductal carcinomas (<xref ref-type="fig" rid="fig2">Figures 2E,F</xref> and <xref ref-type="fig" rid="fig6">6E,F</xref>).</p><p>Although our functional data cover too few patients with mucinous adenocarcinomas (n=5) to perform a formal comparison with the other histopathologies, the pattern of pH<sub>i</sub> regulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) was similar to that observed in invasive lobular and ductal breast carcinomas (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>). Notably, the net acid extrusion capacity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B,C</xref>) and steady-state pH<sub>i</sub> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>) in mucinous adenocarcinomas confirmed the dual dependency on Na<sup>+</sup>/H<sup>+</sup> exchange and Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport.</p></sec><sec id="s2-3"><title>Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport elevates pH<sub>i</sub> more in breast carcinomas of high malignancy grade</title><p>Malignancy grading of breast cancer tissue provides valuable prognostic information (<xref ref-type="bibr" rid="bib57">Rakha et al., 2010</xref>), and we show here that the malignancy grade is also reflected in the pH<sub>i</sub> dynamics of the breast cancer tissue (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>). We observed a tendency toward a greater net acid extrusion capacity in higher malignancy grade breast carcinomas (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig6">Figure 6D</xref>). More prominently, we found that the Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity established an increasingly elevated steady-state pH<sub>i</sub> in breast carcinomas with higher malignancy grade, and this effect reached statistical significance both before (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) and after (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) adjustment for other clinicopathological characteristics.</p><p>Protein expression levels for NHE1 and NBCn1 did not significantly differ between breast cancer tissue of different malignancy grades (<xref ref-type="fig" rid="fig3">Figures 3F,G</xref> and <xref ref-type="fig" rid="fig6">6E,F</xref>).</p></sec><sec id="s2-4"><title>Na<sup>+</sup>/H<sup>+</sup> exchange elevates pH<sub>i</sub> more in breast carcinomas with low estrogen receptor expression</title><p>Estrogen receptors play important roles in mammary gland development (<xref ref-type="bibr" rid="bib65">Shyamala, 1997</xref>). The expression of estrogen receptors in breast cancer tissue varied considerably between patients: as shown in <xref ref-type="table" rid="table1">Table 1</xref>, there was a clear distinction between a large group of patients with tumors showing widespread estrogen receptor expression (≥90% positive cells) and a smaller subset of patients with tumors showing very limited estrogen receptor expression (≤15% positive cells). Previous studies have found that estrogen receptors are expressed in around 10% of the cells in normal breast epithelium (<xref ref-type="bibr" rid="bib44">Oh et al., 2017</xref>).</p><p>We detected no obvious effect of estrogen receptor expression on the net acid extrusion capacity of human breast cancer tissue during intracellular acidification (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig6">Figure 6C,D</xref>). However, as illustrated in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, we observed elevated steady-state pH<sub>i</sub> in breast cancer tissue with no or very low expression (0–15% ER<sup>+</sup>) compared to breast cancer tissue with high expression (90–100% ER<sup>+</sup>) of estrogen receptors. This effect was explained by a greater contribution of Na<sup>+</sup>/H<sup>+</sup> exchange activity—as it was evident both in the presence and absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>—and became statistically significant after adjustment for other clinicopathological characteristics (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><p>The protein expression levels for NHE1 and NBCn1 were not significantly influenced by estrogen receptor status (<xref ref-type="fig" rid="fig4">Figures 4E,F</xref> and <xref ref-type="fig" rid="fig6">6E,F</xref>).</p></sec><sec id="s2-5"><title>HER2 receptors increase expression of NBCn1 and NHE1 protein</title><p>Growth factor input facilitates cancer cell proliferation and the malignant phenotype of cancer cells; and the functional implications of HER2 receptors are amplified by overexpression or gene amplification in 10–20% of breast cancer patients (<xref ref-type="table" rid="table1">Table 1</xref>) and less commonly by activating somatic mutations (<xref ref-type="bibr" rid="bib23">Connell and Doherty, 2017</xref>).</p><p>HER2 receptor status did not significantly influence the net acid extrusion capacity of breast cancer tissue during intracellular acidification (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Whereas we observed a strong tendency toward a higher CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent rise in steady-state pH<sub>i</sub> in HER2-positive tumors (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), this effect was substantially attenuated when adjusted for other clinicopathological characteristics (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><p>The protein expression levels of NHE1 as well as NBCn1 were elevated in breast carcinomas with HER2 overexpression or gene amplification both before (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>) and after (<xref ref-type="fig" rid="fig6">Figure 6E,F</xref>) adjustment for other clinicopathological characteristics.</p></sec><sec id="s2-6"><title>Patient age and tumor size</title><p>We next plotted steady-state pH<sub>i</sub> levels (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A,B</xref>) and capacities for net acid extrusion during intracellular acidification (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C,D</xref>) as functions of tumor size (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A,C</xref>) and patient age (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B,D</xref>). The CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-independent net acid extrusion capacity decreased as function of patient age before (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>) but not after (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) adjustment for other clinicopathological characteristics, whereas none of the other plots revealed significant correlations (<xref ref-type="fig" rid="fig6">Figure 6A–D</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A–D</xref>).</p></sec><sec id="s2-7"><title>Clinicopathological characteristics independently predict acid-base dynamics and expression of acid-base transporters</title><p>The patient groups illustrated in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig5">5</xref> are stratified by individual clinicopathological parameters. We next performed multiple linear and logistic regression analyses to control for multiple comparisons, take into account unbalanced distributions within individual groups, and identify clinical and pathological characteristics that independently predict steady-state pH<sub>i</sub> (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>), net acid extrusion capacity (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>), or acid-base transporter expression (<xref ref-type="fig" rid="fig6">Figure 6E,F</xref>).</p><p>Estrogen receptor status was the predominant influence on steady-state pH<sub>i</sub> in absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), whereas histology and malignancy grade were the predominant modifiers of the CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent increase in steady-state pH<sub>i</sub> (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><p>None of the tested clinical or pathological parameters (i.e., patient age, tumor size, histology, malignancy grade, estrogen receptor status, HER2 status) showed independent value to predict the capacity for CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-independent net acid extrusion mediated by Na<sup>+</sup>/H<sup>+</sup> exchange (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) or the capacity for CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent net acid extrusion mediated by Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) during intracellular acidification.</p><p>The NHE1 and NBCn1 protein expression levels in the human breast cancer tissue were independently elevated by HER2 overexpression or gene amplification (<xref ref-type="fig" rid="fig6">Figure 6E,F</xref>).</p></sec><sec id="s2-8"><title>Elevated pH<sub>i</sub> predicts high proliferative activity</title><p>The accentuated metabolism of cancer cells supplies chemical intermediates and energy for cell proliferation. However, the accelerated metabolism also leads to a higher cellular acid load and risk of intracellular acidification, which can limit further cell proliferation (<xref ref-type="bibr" rid="bib16">Boedtkjer and Pedersen, 2020</xref>).</p><p>When we stratified the patient cohort by expression of proliferative markers (<xref ref-type="fig" rid="fig7">Figure 7A–D</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), tumors with high Ki67 index had more elevated steady-state pH<sub>i</sub> than tumors with low Ki67 index under experimental conditions where Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport was active (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). In contrast, we saw no difference in steady-state pH<sub>i</sub> between the groups in nominal absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). The measured CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent rise in pH<sub>i</sub> carried independent predictive value (odds ratio of 3.12 for a 0.1 increase in pH) to the identification of patients with elevated Ki67 index (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). The rate of pH<sub>i</sub> recovery and capacity for net acid extrusion during intracellular acidification did not differ between tumors with high and low Ki67 index (<xref ref-type="fig" rid="fig7">Figure 7C</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p><p>We demonstrated elevated NBCn1 protein expression in the patient group with high compared to low Ki67 index (<xref ref-type="fig" rid="fig7">Figure 7F</xref>) although this effect was not quite significant after we adjusted for other clinicopathological characteristics (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). We found no difference in NHE1 protein expression between tumors with high and low Ki67 index (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p></sec><sec id="s2-9"><title>Increased Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport capacity and NBCn1 expression predict lymph node metastasis</title><p>Breast cancer prognosis critically depends on the invasive potential of the cancer cells, and acid-base transporters are implicated in key metastatic steps including cell migration and extracellular matrix degradation (<xref ref-type="bibr" rid="bib16">Boedtkjer and Pedersen, 2020</xref>). Thus, we evaluated whether expression and function of acid-base transporters varied between primary breast cancer tissue from patients with and without lymph node metastases (<xref ref-type="fig" rid="fig8">Figure 8</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). We compared primary breast cancer tissue from patients without detectable tumor cells in the axillary lymph nodes to primary breast cancer tissue from patients with axillary lymph nodes containing macro-metastases, micro-metastases, or isolated tumor cells.</p><p>The initial CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-dependent pH<sub>i</sub> recovery from NH<sub>4</sub><sup>+</sup>-prepulse-induced intracellular acidification (<xref ref-type="fig" rid="fig8">Figure 8A,B</xref>) and the corresponding Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity (<xref ref-type="fig" rid="fig8">Figure 8C</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>) were accelerated in primary breast cancer tissue from patients with axillary lymph node metastases. The Na<sup>+</sup>,HCO<sub>3</sub><sup>– </sup>cotransport activity quantified at pH<sub>i </sub>6.5–6.6 carried independent predictive value to identify patients with axillary lymph node metastases (odds ratio of 1.54 for each 10 mM/min increase; <xref ref-type="fig" rid="fig8">Figure 8G</xref>). The capacity of the human primary breast carcinomas for Na<sup>+</sup>/H<sup>+</sup> exchange activity was not significantly different between patients with and without detected lymph node metastases (<xref ref-type="fig" rid="fig8">Figure 8C,G</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). We also did not observe any differences in steady-state pH<sub>i</sub>—in the presence or absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>—between primary breast carcinomas from patients with or without identified axillary lymph node metastases (<xref ref-type="fig" rid="fig8">Figure 8D,G</xref>).</p><p>In congruence with the enhanced Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity, we identified increased NBCn1 protein expression in primary breast cancer tissue from patients with lymph node metastases (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). Thus, elevated NBCn1 protein expression was an independent predictor of lymph node metastasis with an odds ratio of 1.72 for a single-unit step increase on the applied 6-point expression scale (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). The selective importance of Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport and NBCn1 expression was supported by our finding that NHE1 protein expression was reduced in primary breast cancer tissue from patients with lymph node metastases (<xref ref-type="fig" rid="fig8">Figure 8E</xref>) and qualified as an independent predictor negatively related to metastatic risk with an odds ratio of 0.60 (<xref ref-type="fig" rid="fig8">Figure 8G</xref>).</p></sec><sec id="s2-10"><title>mRNA expression levels for acid-base transporters predict patient survival</title><p>We next evaluated whether the biological implications of acid-base transporters in breast cancer tissue have consequences for patient prognosis. We used transcriptomics data to stratify a patient cohort of nearly 1500 breast cancer patients by their mRNA expression levels for acid-base transporters. We then studied how the survival proportions developed over time in the entire patient population and in subpopulations with well-defined molecular subtypes (i.e., normal-like, luminal A and B, HER2-enriched, and basal-like breast cancer). We expect no straightforward proportionality between mRNA, protein, and function when comparing across molecular subtypes or clinicopathological characteristics driven by different carcinogenic mechanisms. This should be kept in mind particularly when interpreting survival analyses performed across the whole unstratified patient population (<xref ref-type="fig" rid="fig9">Figures 9B</xref> and <xref ref-type="fig" rid="fig10">10B</xref>, and <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplements 1B</xref> and <xref ref-type="fig" rid="fig10s2">2B</xref>). Focusing on individual molecular subtypes, the relationship from mRNA to protein and function is likely much simpler, and our emphasis is therefore on the survival analyses performed after molecular subtype stratification (<xref ref-type="fig" rid="fig9">Figure 9C–G</xref>, <xref ref-type="fig" rid="fig10">Figure 10C–G</xref>, and <xref ref-type="fig" rid="fig10s2">Figure 10—figure supplements 1C–G and 2C–G</xref>).</p><p>The breast cancer molecular subtypes reflect differences in sex hormone (estrogen and progesterone; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A,B</xref>) and growth factor (HER2; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1C</xref>) receptor expression. The individual breast cancer molecular subtypes also showed systematic differences in expression of proliferative markers (<italic>MKI67</italic> mRNA; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1D</xref>) and lactate dehydrogenase involved in fermentative glycolysis (<italic>LDHA</italic> mRNA; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1E</xref>), consistent with the notion that malignancy gradually increases from normal-like and luminal A across luminal B and HER2-enriched to basal-like breast cancer (<xref ref-type="bibr" rid="bib24">Dai et al., 2015</xref>). In contrast, the angiogenic markers <italic>PECAM1</italic> and <italic>CD34</italic> showed the highest mRNA expression in normal-like breast cancer (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1F,G</xref>).</p><p>The level of <italic>SLC9A1</italic> mRNA, encoding NHE1, was most abundant in normal-like, luminal A, and HER2-enriched breast cancer, lower in luminal B breast cancer, and lowest in basal-like breast cancer (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). The <italic>SLC9A1</italic> mRNA expression level was not associated with altered survival for the whole population of breast cancer patients (<xref ref-type="fig" rid="fig9">Figure 9B</xref>) or for breast cancer patients suffering from normal-like (<xref ref-type="fig" rid="fig9">Figure 9C</xref>), luminal B (<xref ref-type="fig" rid="fig9">Figure 9E</xref>), HER2-enriched (<xref ref-type="fig" rid="fig9">Figure 9F</xref>), or basal-like (<xref ref-type="fig" rid="fig9">Figure 9G</xref>) breast cancer. However, patients with high <italic>SLC9A1</italic> mRNA expression suffering from luminal A breast cancer showed significantly improved survival (hazard ratio 0.552) compared to patients with low <italic>SLC9A1</italic> mRNA expression (<xref ref-type="fig" rid="fig9">Figure 9D</xref>), which is consistent with our observation of reduced lymph node metastasis among patients with high NHE1 protein expression (<xref ref-type="fig" rid="fig8">Figure 8G</xref>).</p><p><italic>SLC4A7</italic> mRNA, encoding NBCn1, was expressed at the highest level in luminal A breast cancer, at intermediate level in normal-like and luminal B breast cancer, and at lowest level in HER2-enriched and basal-like breast cancer (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). The high overall <italic>SLC4A7</italic> expression level in luminal A breast cancer argues for a prominent role of NBCn1 in this breast cancer molecular subtype and suggests that the upregulation of NBCn1 in this molecular subtype largely occurs due to transcriptional regulation. Indeed, we observed significantly shortened survival times (hazard ratio 2.18) for the luminal A breast cancer patients with the highest compared to the lowest <italic>SLC4A7</italic> mRNA levels (<xref ref-type="fig" rid="fig10">Figure 10D</xref>). Even though expression of <italic>SLC4A7</italic> mRNA was relatively low in basal-like breast cancer, we also observed a significantly worse prognosis (hazard ratio 2.14) for patients with the highest <italic>SLC4A7</italic> mRNA levels within this breast cancer subtype (<xref ref-type="fig" rid="fig10">Figure 10G</xref>). The importance of NBCn1 in basal-like breast cancer is likely explained by the high proliferative and glycolytic activity (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1D,E</xref>), which will expectedly elevate the cellular acid load and thus the requirement for net acid extrusion. Shorter survival of breast cancer patients with high expression of <italic>SLC4A7</italic> mRNA (<xref ref-type="fig" rid="fig10">Figure 10D,G</xref>) is consistent with the greater tendency for lymph node metastasis among patients with high NBCn1 protein expression and accelerated Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport (<xref ref-type="fig" rid="fig8">Figure 8G</xref>) as well as with the enhanced proliferative activity in patients with elevated steady-state pH<sub>i</sub> due to Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). For patients with normal-like (<xref ref-type="fig" rid="fig10">Figure 10C</xref>), luminal B (<xref ref-type="fig" rid="fig10">Figure 10E</xref>), and HER2-enriched (<xref ref-type="fig" rid="fig10">Figure 10F</xref>) breast cancer, we saw no association of <italic>SLC4A7</italic> mRNA expression with survival. We also observed no overall survival differences according to the <italic>SLC4A7</italic> mRNA expression level across the whole unstratified population of breast cancer patients (<xref ref-type="fig" rid="fig10">Figure 10B</xref>) where the survival effects of differences in <italic>SLC4A7</italic> transcript levels within specific molecular subgroups are diluted in the larger patient population.</p><p>Monocarboxylate transporters play roles in eliminating lactate and associated H<sup>+</sup> from cells relying on fermentative glycolysis and allow neighboring cells to take up and metabolize the lactate through oxidation (<xref ref-type="bibr" rid="bib52">Pérez-Escuredo et al., 2016</xref>). Thus, the monocarboxylate transporters could influence intra- and extracellular acid-base conditions as well as cellular energy levels in solid cancer tissue (<xref ref-type="bibr" rid="bib16">Boedtkjer and Pedersen, 2020</xref>). <italic>SLC16A1</italic> mRNA (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A</xref>), encoding MCT1, and <italic>SLC16A3</italic> mRNA (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2A</xref>), encoding MCT4, both showed high expression levels in basal-like breast cancer characterized by high proliferative (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1D</xref>) and glycolytic (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1E</xref>) activity. In contrast, <italic>SLC16A3</italic> mRNA expression was high (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2A</xref>) and <italic>SLC16A1</italic> mRNA expression very low (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A</xref>) in luminal B breast cancer tissue. Notably, although <italic>SLC16A1</italic> mRNA levels showed no association with breast cancer survival (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1B–G</xref>), high <italic>SLC16A3</italic> mRNA levels were significantly associated with—or showed tendency toward—poor survival in all breast cancer molecular subtypes (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2B,C and E–G</xref>) except for luminal A (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2D</xref>).</p><p>Even though the expression of the investigated acid-base transporters vary systematically across the molecular subtypes (<xref ref-type="fig" rid="fig9">Figures 9A</xref> and <xref ref-type="fig" rid="fig10">10A</xref>, <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplements 1A</xref> and <xref ref-type="fig" rid="fig10s2">2A</xref>), the transcript levels for <italic>SLC4A7</italic>, <italic>SLC9A1</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic> showed no significant pairwise correlation when controlled for the patterns of <italic>ERBB2</italic>, <italic>ESR1</italic>, and <italic>PGR</italic> mRNA expression (<xref ref-type="supplementary-material" rid="fig9sdata1">Figure 9—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig10sdata1">Figure 10—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig10s1sdata1">Figure 10—figure supplement 1—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig10s2sdata1">Figure 10—figure supplement 2—source data 1</xref>). This observation supports that the acid-base transporters independently modify survival when analyzed for each of the breast cancer molecular subtypes separately.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We report here on the first large-scale study of pH<sub>i</sub> dynamics in human cancer samples. We demonstrate that acid-base transporters play key pathophysiological roles by counteracting intracellular acidification and setting the steady-state pH<sub>i</sub> in human breast cancer tissue (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Furthermore, the level of cellular acidity and the capacity for net acid extrusion in human primary breast carcinomas can account for variation in proliferative activity (<xref ref-type="fig" rid="fig7">Figure 7</xref>) and are predictive for the occurrence of lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The functional recordings of pH<sub>i</sub> dynamics carry predictive value that is complementary to and independent from information based on protein expression analyses (<xref ref-type="fig" rid="fig7">Figures 7G</xref> and <xref ref-type="fig" rid="fig8">8G</xref>).</p><p>We detect substantial inter-patient heterogeneity in acid-base conditions of breast carcinomas and explore the underlying modifiers and biological consequences. As illustrated in <xref ref-type="fig" rid="fig11">Figure 11</xref>, we show that (a) Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport raises pH<sub>i</sub> more in invasive lobular than ductal breast carcinomas and particularly in breast cancer tissue of high malignancy grade (<xref ref-type="fig" rid="fig2">Figures 2</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig6">6</xref>); (b) Na<sup>+</sup>/H<sup>+</sup> exchange raises pH<sub>i</sub> more in estrogen receptor-negative breast carcinomas (<xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig6">6</xref>); (c) protein expression of NBCn1 and NHE1 is elevated by HER2 overexpression or gene amplification (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>); (d) elevated steady-state pH<sub>i</sub> particularly due to Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport predicts high proliferative activity in primary breast carcinomas (<xref ref-type="fig" rid="fig7">Figure 7</xref>); (e) elevated capacity for Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport, high NBCn1 protein expression, and low NHE1 protein expression predict lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8</xref>); and (f) high <italic>SLC4A7</italic> and/or low <italic>SLC9A1</italic> mRNA expression are associated with shorter survival in patients with luminal A and basal-like/triple-negative breast cancer (<xref ref-type="fig" rid="fig9">Figures 9</xref> and <xref ref-type="fig" rid="fig10">10</xref>).</p><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>Schematics summarizing identified interactions and associated functional implications of NHE1 (upper panel) and NBCn1 (lower panel) in human breast cancer.</title><p>The image was generated with <ext-link ext-link-type="uri" xlink:href="http://biorender.com/">BioRender.com</ext-link>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68447-fig11-v2.tif"/></fig><p>Supporting the validity of our study, the findings are based on two distinct patient populations evaluated by separate experimental approaches: (a) the links between pH<sub>i</sub> dynamics, protein expression of acid-base transporters, and clinical and pathological patient characteristics (<xref ref-type="fig" rid="fig1">Figures 1</xref>–<xref ref-type="fig" rid="fig8">8</xref>) come from a cohort of 110 breast cancer patients with information derived from medical records, pH<sub>i</sub> recordings, and immunohistochemical staining; and (b) the prognostic evidence linking transcriptomics data to patient survival (<xref ref-type="fig" rid="fig9">Figures 9</xref> and <xref ref-type="fig" rid="fig10">10</xref>) comes from a separate cohort of 1457 breast cancer patients.</p><p>As depicted schematically in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, HCO<sub>3</sub><sup>–</sup> uptake via NBCn1 is functionally equivalent to H<sup>+</sup> extrusion via NHE1 when the CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> buffer is in equilibrium (<xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>). However, as summarized in <xref ref-type="fig" rid="fig11">Figure 11</xref>, it is clear from our analyses that NBCn1 and NHE1 have very different consequences in human breast cancer tissue: Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport sets the steady-state pH<sub>i</sub> associated with proliferative activity (<xref ref-type="fig" rid="fig7">Figure 7G</xref>); and the capacity for Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport and protein expression of NBCn1 predict lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). In contrast, steady-state pH<sub>i</sub> in absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> and the capacity for Na<sup>+</sup>/H<sup>+</sup> exchange show no relation to proliferation (<xref ref-type="fig" rid="fig7">Figure 7G</xref>) or metastasis (<xref ref-type="fig" rid="fig8">Figure 8G</xref>); and the protein expression of NHE1 is even negatively related to axillary lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). Accordingly, high <italic>SLC4A7</italic> but low <italic>SLC9A1</italic> mRNA expression is associated with poor survival in select breast cancer molecular subtypes (<xref ref-type="fig" rid="fig9">Figures 9</xref> and <xref ref-type="fig" rid="fig10">10</xref>). Although the reason for these marked differences between NBCn1 and NHE1 is not yet entirely clear, distinct cellular and subcellular expression patterns (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Lauritzen et al., 2012</xref>), allosteric regulation by pH<sub>i</sub> and pH<sub>o</sub> (<xref ref-type="bibr" rid="bib17">Bonde and Boedtkjer, 2017</xref>; <xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Hulikova et al., 2011</xref>), molecular interacting partners, and responses to auto-, para-, and endocrine signals (<xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Boedtkjer and Aalkjaer, 2009</xref>; <xref ref-type="bibr" rid="bib26">Danielsen et al., 2013</xref>) likely play important roles.</p><p>The impact of global steady-state pH<sub>i</sub> on cell proliferation (<xref ref-type="fig" rid="fig7">Figure 7G</xref>) is consistent with earlier observations from cultured cell lines that cell cycle progression requires a permissive pH<sub>i</sub> in the slightly alkaline range (<xref ref-type="bibr" rid="bib27">Flinck et al., 2018</xref>). Low pH<sub>i</sub> inhibits the enhanced DNA and protein synthesis preceding cell division although the exact molecular mechanisms have not yet been conclusively identified (<xref ref-type="bibr" rid="bib12">Boedtkjer, 2019</xref>; <xref ref-type="bibr" rid="bib15">Boedtkjer and Aalkjaer, 2013</xref>; <xref ref-type="bibr" rid="bib56">Pouysségur et al., 1985</xref>; <xref ref-type="bibr" rid="bib43">Ober and Pardee, 1987</xref>). We previously found that knockout of NBCn1 inhibits cell proliferation in murine breast cancer tissue, particularly in deep tumor regions and larger-sized tumors where fermentative glycolysis dominates and the cellular metabolic acid load is elevated (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>).</p><p>Variation in the rate of acidic metabolic waste production and in the capacity for net acid extrusion shapes the local chemical environment and thereby influences the cancer cell phenotype important for disease progression. There is evidence that local pH<sub>i</sub> induces cytoskeletal rearrangements (<xref ref-type="bibr" rid="bib6">Bernstein et al., 2000</xref>; <xref ref-type="bibr" rid="bib55">Pope et al., 2004</xref>) and that cell surface pH modifies cell-cell and cell-matrix interactions (<xref ref-type="bibr" rid="bib58">Riemann et al., 2019</xref>; <xref ref-type="bibr" rid="bib70">Stock et al., 2007</xref>), which in combination with acid-induced degradation of the extracellular matrix (<xref ref-type="bibr" rid="bib59">Rofstad et al., 2006</xref>) can promote directional migration and metastasis. Differences in cell surface pH along the axis of migration have been reported for various migrating cells in culture based on differences in expression and activity of acid-base transporters between leading and rear ends (<xref ref-type="bibr" rid="bib64">Schwab et al., 2012</xref>). We have previously found that migrating vascular smooth muscle cells generate NBCn1-dependent spatial pH gradients that are critical for directional migration (<xref ref-type="bibr" rid="bib11">Boedtkjer et al., 2016</xref>), and the role of NBCn1 was subsequently supported by a study on a lung adenocarcinoma cell line (<xref ref-type="bibr" rid="bib33">Hwang et al., 2020</xref>). Our current findings (<xref ref-type="fig" rid="fig8">Figure 8G</xref>) suggest that NBCn1-mediated Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport plays a similar role for the invasiveness of human breast cancer cells. Interestingly, the cellular capacity for net acid extrusion was not associated with other of the tested clinicopathological characteristics (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>), which supports that NBCn1 independently impact the metastatic potential of breast cancer cells (<xref ref-type="fig" rid="fig8">Figure 8G</xref>).</p><p>Based on the negative relationship between NHE1 expression and lymph node metastasis (<xref ref-type="fig" rid="fig8">Figure 8G</xref>) and considering the improved survival of luminal A breast cancer patients with high <italic>SLC9A1</italic> expression (<xref ref-type="fig" rid="fig9">Figure 9D</xref>), we propose that NHE1 is a metastasis suppressor in human breast cancer. Metastasis suppressor proteins are frequently upregulated in early cancer disease, as their expression is lost during cancer progression rather than malignant transformation (<xref ref-type="bibr" rid="bib66">Smith and Theodorescu, 2009</xref>; <xref ref-type="bibr" rid="bib29">Guo et al., 1996</xref>). The spatiotemporal regulation of NHE1 expression during breast cancer development has not been investigated in detail. In studies of murine carcinogen-induced breast cancer, NHE1 protein levels were unchanged in the primary cancer tissue compared to normal breast tissue and showed a tendency to decline with increasing tumor size (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>). In previous studies on human breast cancer tissue, NHE1 protein expression was very high in ductal carcinoma in situ lesions and elevated in early primary breast carcinomas, yet showed a tendency to decrease during metastatic progression (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>). In the same human biopsy material, NBCn1 showed a continuous trend for progressively increasing protein levels from normal breast tissue, over primary breast carcinomas, to metastatic lesions (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>). Previous investigations in MCF7 human breast cancer cells support the functional consequences of NHE1 observed in our human breast cancer cohort: NHE1 protein expression in the MCF7 cells markedly increased during heterologous overexpression of an amino-truncated ErbB2 receptor (<xref ref-type="bibr" rid="bib36">Lauritzen et al., 2010</xref>), yet pharmacological inhibition of NHE1 under these conditions stimulated cell migration (<xref ref-type="bibr" rid="bib37">Lauritzen et al., 2012</xref>).</p><p>Acid-base transporters play a key role for eliminating metabolic acidic waste, and hence their pathophysiological impact depends on the metabolic activity in the specific cancer tissue. This is particularly evident in triple-negative breast cancer that shows an overall low expression of <italic>SLC4A7</italic> mRNA (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). Nonetheless, the survival of triple-negative breast cancer patients is sensitive to variation in <italic>SLC4A7</italic> transcript levels (<xref ref-type="fig" rid="fig10">Figure 10G</xref>) most likely due to high proliferative and metabolic activities (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>) that challenge pH<sub>i</sub> homeostasis. This observation supports that selectivity of anti-cancer therapies targeting acid-base transporters can be conferred not only by dramatic overexpression in cancer tissue relative to other tissues in the body but also by a greater functional dependency on net acid extrusion capacity in the cancer tissue. Pharmacological inhibitors of acid-base transporters have not yet reached clinical use. Previously described small molecule inhibitors of NBCn1 (e.g., S0859) do not provide the selectivity or pharmacokinetic properties necessary for systemic therapy (<xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Larsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Steinkamp et al., 2015</xref>); and whereas NHE1 inhibitors (e.g., cariporide, eniporide) reached phase 3 clinical studies for ischemic heart disease (<xref ref-type="bibr" rid="bib42">Mentzer et al., 2008</xref>; <xref ref-type="bibr" rid="bib84">Zeymer et al., 2001</xref>), they have not been sufficiently explored for cancer therapy. Recently developed inhibitors of monocarboxylate transporters show initial experimental promise as anti-cancer drugs (<xref ref-type="bibr" rid="bib5">Beloueche-Babari et al., 2017</xref>).</p><p>Most current diagnostic procedures and selection of patients for targeted therapy (e.g., based on HER2 or estrogen receptors) rely on analysis of protein expression in fixed tissue. The current study validates that quantitative protein activity measurements and evaluation of functional contribution from specific molecular targets in viable tissue preparations provide additional clinically and prognostically important information. The independent information carried by RNA expression, protein expression, and acid-base transport activity suggests that considerable regulation occurs at translational and post-translational levels. The pH<sub>i</sub> dynamics in the tumor tissue can therefore not be directly deduced from data on protein or gene expression. It is especially noticeable that the protein expression levels of NBCn1 and NHE1 (<xref ref-type="fig" rid="fig5">Figures 5E,F</xref> and <xref ref-type="fig" rid="fig6">6E,F</xref>) are elevated in breast cancer tissue with HER2 overexpression or gene amplification despite low <italic>SLC4A7</italic> and intermediate <italic>SLC9A1</italic> mRNA levels (<xref ref-type="fig" rid="fig9">Figures 9A</xref> and <xref ref-type="fig" rid="fig10">10A</xref>). For NBCn1, this inverse relationship between mRNA and protein expression is in congruence with previous reports from murine breast cancer tissue where ErbB2 overexpression is associated with significantly elevated NBCn1 protein levels despite a drastically decreased <italic>Slc4a7</italic> mRNA level compared to normal breast tissue (<xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>). Thus, increased translational activity or protein stability must be responsible for the raised NBCn1 protein levels in HER2-enriched breast cancer tissue. Because the <italic>SLC4A7</italic> mRNA level—based on the abovementioned considerations—does not reflect the NBCn1 protein level or functional capacity in HER2-enriched breast cancer, the survival analysis based on <italic>SLC4A7</italic> mRNA expression (<xref ref-type="fig" rid="fig10">Figure 10F</xref>) should be interpreted with caution for this molecular subtype. Even without a link between <italic>SLC4A7</italic> mRNA expression and survival, the NBCn1 protein expression level and functional capacity could influence patient prognosis.</p><p>In light of the widespread use of HER2-targeted breast cancer therapy, it is intriguing that HER2 signaling shows apparently opposing effects on breast cancer progression by concurrently upregulating the protein expression of NBCn1 and NHE1 (<xref ref-type="fig" rid="fig5">Figures 5E,F</xref> and <xref ref-type="fig" rid="fig8">8G</xref>). Our findings indicate that (a) additional detailed analysis of downstream signaling effects (e.g., relative upregulation of NBCn1 vs. NHE1) may provide more accurate predictive value than simple evaluation of HER2 overexpression and gene amplification and (b) selective targeting of individual HER2-activated effectors—including acid-base transporters—could optimize the current therapeutic approach based on direct HER2 inhibition.</p><p>Luminal A breast cancer differs from other breast cancer molecular subtypes in the profile whereby expression of acid-base transporters influences mortality rates. Elevated mRNA expression of <italic>SLC4A7</italic> impedes (<xref ref-type="fig" rid="fig10">Figure 10D</xref>), <italic>SLC9A1</italic> improves (<xref ref-type="fig" rid="fig9">Figure 9D</xref>), whereas <italic>SLC16A1</italic> and <italic>SLC16A3</italic> show no influence on (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplements 1D</xref> and <xref ref-type="fig" rid="fig10s2">2D</xref>) patient survival in luminal A breast cancer. The observation regarding <italic>SLC16A3</italic> is notable because high expression worsens (or tends to worsen) patient prognosis in the other breast cancer molecular subtypes (<xref ref-type="fig" rid="fig10s2">Figure 10—figure supplement 2C and E–G</xref>). Luminal A breast cancer comprises 50–70% of breast cancer cases in the United States and Europe (<xref ref-type="bibr" rid="bib34">Kulkarni et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Acheampong et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Valla et al., 2016</xref>) and is clinically interesting because distant metastasis occurs throughout follow-up for as long as 25 years after initial diagnosis (<xref ref-type="bibr" rid="bib83">Yu et al., 2019</xref>). This is different from, for instance, luminal B breast cancer where the risk of metastasis is high the first 5 years after diagnosis but then markedly declines (<xref ref-type="bibr" rid="bib83">Yu et al., 2019</xref>). Given the identified link between acid-base conditions and metastasis (<xref ref-type="fig" rid="fig8">Figure 8</xref>), the distinct prognostic dependency of luminal A breast cancer patients on expression of acid-base transporters could hold a key to the underlying pathophysiology resulting in protracted metastatic risk.</p><p>Invasive lobular carcinomas show diffusely infiltrative growth patterns that differ from the dominant masses typical for invasive ductal carcinomas (<xref ref-type="bibr" rid="bib75">Thomas et al., 2019</xref>). Lost expression of the cell-cell adhesion molecule E-cadherin can explain the tendency for cancer cells from lobular carcinomas to invade in single file (<xref ref-type="bibr" rid="bib28">Gamallo et al., 1993</xref>; <xref ref-type="bibr" rid="bib47">Pai et al., 2013</xref>), which is more difficult to delineate by mammography, and thus account for the higher positive surgical margin rates following lumpectomy procedures (<xref ref-type="bibr" rid="bib78">van Deurzen, 2016</xref>). More efficient net acid extrusion in lobular compared to ductal breast carcinomas is evident from the greater elevation of pH<sub>i</sub> by Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig6">6</xref>) and likely translates to enhanced extracellular acidification. Thus, based on the downregulation of E-cadherin expression in response to extracellular acidosis—previously identified in cultured cell lines (<xref ref-type="bibr" rid="bib58">Riemann et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Suzuki et al., 2014</xref>)—it is an intriguing possibility that cellular acid-base handling in human breast carcinomas shapes the histology characteristic growth patterns.</p><p>To our knowledge, the current study reports from the largest existing human cancer cohort (<xref ref-type="table" rid="table1">Table 1</xref>) with detailed cellular acid-base information. Still, the size of the cohort comes with some limitations. Mortality rates for breast cancer patients undergoing breast-conserving surgery are generally low (<xref ref-type="bibr" rid="bib46">Onitilo et al., 2015</xref>). Therefore, at currently 2–5 years of follow-up, we are unable to perform meaningful survival analyses linking directly to measurements of pH or protein expression. However, our meta-analysis based on transcriptomics data from larger cohorts with longer follow-up partly compensates for this limitation (<xref ref-type="fig" rid="fig9">Figures 9</xref> and <xref ref-type="fig" rid="fig10">10</xref>, and <xref ref-type="fig" rid="fig10s1">Figure 10—figure supplements 1</xref> and <xref ref-type="fig" rid="fig10s2">2</xref>). In addition, despite the large overall cohort size, we are for the individual subgroup analyses limited by the natural incidence of specific clinicopathological characteristics. For some of the less frequent characteristics—e.g., rarer histological types (<xref ref-type="table" rid="table1">Table 1</xref>)—the subgroups are too small for statistical comparison.</p><p>Whereas the short delay from tissue isolation to functional evaluation is a unique strength of the current study—because it minimizes the risk of phenotypical changes and thereby strengthens the connection to the clinical condition—it limits the experimental possibilities for detailed mechanistic and molecular studies. The experimental setup allows for manipulation and precise control of the buffer compositions; but with half-lives of protein degradation of 76 and 48 hr for NBCn1 and NHE1, respectively (<xref ref-type="bibr" rid="bib45">Olesen et al., 2018</xref>), we cannot realistically reduce overall cellular protein levels by interfering with their expression—e.g., by RNAi knockdown technologies (<xref ref-type="bibr" rid="bib8">Boedtkjer et al., 2006</xref>)—in the human biopsy material. Also, the available pharmacological options are too unspecific and without selectivity for individual Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporters (<xref ref-type="bibr" rid="bib11">Boedtkjer et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Larsen et al., 2012</xref>). Still, our previous studies confirm that the Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport in human breast cancer tissue is of low 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid sensitivity (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>), which is a pharmacological characteristic of NBCn1 relative to other Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporters (<xref ref-type="bibr" rid="bib9">Boedtkjer et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Choi et al., 2000</xref>; <xref ref-type="bibr" rid="bib61">Romero et al., 2004</xref>). This pharmacological profile thus corroborates strong recent molecular evidence—based on gene knockout technology—that the upregulated Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport in two different murine breast cancer models completely depends on NBCn1 (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>).</p><p>In conclusion, we identify distinct patterns of pH<sub>i</sub> dynamics as well as mRNA and protein expression of acid-base transporters among breast cancer patients based on clinical and pathological characteristics and molecular subtypes. The mechanisms of acidic waste product elimination reflect the heterogeneity in human breast cancer tissue. Dependency on Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport for steady-state pH<sub>i</sub> regulation independently predicts proliferative activity, whereas the capacity for Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransport activity and the expression of NBCn1 predict lymph node metastasis and patient survival. In contrast, NHE1 expression negatively predicts lymph node metastasis and patient survival. Together, these findings underscore the important pathophysiological role of acid-base homeostasis in human breast cancer tissue and emphasize the potential of acid-base transporters as anti-cancer targets.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Homo sapiens</italic>)</td><td valign="top"><italic>SLC4A7</italic></td><td valign="top">GenBank</td><td valign="top">Gene ID: 9497</td><td valign="top">Encodes NBCn1</td></tr><tr><td valign="top">Gene (<italic>Homo sapiens</italic>)</td><td valign="top"><italic>SLC9A1</italic></td><td valign="top">GenBank</td><td valign="top">Gene ID: 6548</td><td valign="top">Encodes NHE1</td></tr><tr><td valign="top">Gene (<italic>Homo sapiens</italic>)</td><td valign="top"><italic>SLC16A1</italic></td><td valign="top">GenBank</td><td valign="top">Gene ID: 6566</td><td valign="top">Encodes MCT1</td></tr><tr><td valign="top">Gene (<italic>Homo sapiens</italic>)</td><td valign="top"><italic>SLC16A3</italic></td><td valign="top">GenBank</td><td valign="top">Gene ID: 9123</td><td valign="top">Encodes MCT4</td></tr><tr><td valign="top">Biological sample (<italic>Homo sapiens</italic>)</td><td valign="top">Surgical breast biopsies</td><td valign="top">Regionshospitalet Randers, Denmark</td><td valign="top">This study cohort</td><td valign="top">Cancer and matched normal tissue</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Collagenase type 3</td><td valign="top">Worthington Biochemical Corporation</td><td valign="top">Cat. #: LS004182</td><td valign="top">450 IU/mL</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">BCECF-AM</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat. #: B1170</td><td valign="top">3 µM</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NBCn1 (Rabbit polyclonal)</td><td valign="top">Jeppe Praetorius, Aarhus University, Denmark <xref ref-type="bibr" rid="bib25">Damkier et al., 2006</xref></td><td valign="top">Reference</td><td valign="top">IHC (1:100)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NHE1 (Mouse monoclonal)</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat. #: sc-136239; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2191254">AB_2191254</ext-link></td><td valign="top">IHC (1:100)</td></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">OptiView DAB IHC detection kit</td><td valign="top">Roche Diagnostics</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2833075">AB_2833075</ext-link></td><td valign="top">Goat anti-rabbit and anti-mouse</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">SPSS</td><td valign="top">IBM</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002865">SCR_002865</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Prism</td><td valign="top">GraphPad</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top">Version 9.1.1</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human breast biopsies</title><p>Viable tissue biopsies of human breast cancer tissue and matched normal breast tissue were obtained from breast-conserving lumpectomies at the Department of Surgery, Regionshospitalet Randers, Denmark, essentially as previously described (<xref ref-type="bibr" rid="bib10">Boedtkjer et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>). We collected samples only from primary breast cancer resections, that is, no samples were acquired from recurrent tumors or metastatic sites. None of the included patients had received pre-operative radiation or chemotherapy. The studies included women, who were at least 18 years of age and presented with operable primary breast cancer (&gt;10 mm) diagnosed by triple test including clinical examination, mammography combined with ultrasonography, and fine-needle aspiration cytology and/or core-needle biopsy. <xref ref-type="table" rid="table1">Table 1</xref> summarizes the clinical and pathological characteristics of the 110 included patients. We obtained information regarding patient age, tumor size, histology, malignancy grade, expression of estrogen receptors, HER2 overexpression or gene amplification, Ki67 index, and lymph node metastasis from the medical records of the standard diagnostic care.</p></sec><sec id="s4-2"><title>Preparation of freshly isolated organoids</title><p>We freshly isolated epithelial organoids—multicellular conglomerates of approximately 150 µm diameter dominated by cytokeratin-19-positive epithelial cells (<xref ref-type="bibr" rid="bib39">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>)—from breast cancer tissue and normal breast tissue through partial collagenase digestion of the collected breast biopsies (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). The tissue samples were first cut into 1 mm pieces in phosphate-buffered saline and then transferred to Tissue Culture Flat Tubes (Techno Plastic Products AG, Switzerland) containing advanced DMEM/F12 culture medium (Life Technologies, Denmark) added 10% fetal bovine serum (Biochrom AG, Germany), 1% GlutaMAX (Thermo Fisher Scientific, Denmark) and 450 IU/mL collagenase type 3 (Worthington Biochemical Corporation, Lakewood, NJ). After continuous overnight shaking at 60 rpm in an incubator with 5% CO<sub>2</sub> at 37°C, the isolated organoids sedimented for 20 min by gravitational forces and were then used directly for experiments without culture in order to best retain the functional characteristics of the sampled breast tissue.</p></sec><sec id="s4-3"><title>pH<sub>i</sub> measurements</title><p>We studied pH<sub>i</sub> dynamics in epithelial organoids—freshly isolated from human breast cancer tissue and normal breast tissue—loaded with the pH-sensitive fluorophore 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF). We added 3 µM acetoxymethyl ester form of BCECF to a physiological saline solution containing 0.1% dimethyl sulfoxide, and loaded the organoids at 37°C for approximately 20 min before they were investigated on the stage of a Nikon Diaphot 200 microscope (Nikon, Japan) equipped with an SRV CCD Retiga camera (QImaging, Canada) and VisiView software (Visitron Systems, Germany). Emission light was collected at 530 nm during alternating excitation at 440 and 495 nm. After background subtraction, the <italic>F</italic><sub>495</sub>/<italic>F</italic><sub>440</sub> BCECF fluorescence ratio was calibrated to pH<sub>i</sub> using the high-[K<sup>+</sup>] nigericin technique (<xref ref-type="bibr" rid="bib74">Thomas et al., 1979</xref>).</p><p>Intracellular acidification was induced with the NH<sub>4</sub><sup>+</sup>-prepulse technique (<xref ref-type="bibr" rid="bib18">Boron and De Weer, 1976</xref>). Using the equation: β=Δ[NH<sub>4</sub><sup>+</sup>]/ΔpH<sub>i</sub>, we calculated the intracellular intrinsic buffering capacity from the change in pH<sub>i</sub> upon addition or washout of NH<sub>4</sub>Cl under CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-free conditions. The contribution of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> to the intracellular buffering power was calculated based on the formula βCO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>=2.3·[HCO<sub>3</sub><sup>–</sup>]<sub>i</sub> (<xref ref-type="bibr" rid="bib62">Roos and Boron, 1981</xref>). Concentrations of NH<sub>4</sub><sup>+</sup> and HCO<sub>3</sub><sup>–</sup> were computed from the Henderson-Hasselbalch equation. We calculated net acid extrusion activity as the product of the total intracellular buffering capacity and the rate of pH<sub>i</sub> recovery from NH<sub>4</sub><sup>+</sup>-prepulse-induced intracellular acidification. Net acid extrusion activities were generally calculated for 30 s intervals covering the full pH<sub>i</sub> recovery phase; but in cases with extreme intracellular acidification (reaching below pH<sub>i</sub> 6.4), we omitted the most acidic phase while maintaining a pH<sub>i</sub> span of no less than 0.1. We plotted net acid extrusion as function of the average pH<sub>i</sub> within the individually analyzed intervals and calculated for each experiment the transport rate at pH<sub>i </sub>6.5–6.6. A few organoids were excluded from the analyses because of insufficient NH<sub>4</sub><sup>+</sup>-prepulse-induced acidification.</p><p>The CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-containing physiological saline solution contained (in mM): 119 NaCl, 22 NaHCO<sub>3</sub>, 10 HEPES, 1.2 MgSO<sub>4</sub>, 2.82 KCl, 5.5 glucose, 1.18 KH<sub>2</sub>PO<sub>4</sub>, 0.03 EDTA, 1.6 CaCl<sub>2</sub>. CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-free solutions were produced by substitution of HCO<sub>3</sub><sup>–</sup> with Cl<sup>–</sup>, whereas Na<sup>+</sup>-free solutions were produced by substitution of Na<sup>+</sup> with <italic>N</italic>-methyl-D-glucammonium (NMDG<sup>+</sup>), except for the NaHCO<sub>3</sub> that was substituted with choline-HCO<sub>3</sub>. All solutions contained 5 mM probenecid to inhibit the organic anion transporter and avoid extrusion of BCECF from the cancer cells (<xref ref-type="bibr" rid="bib38">Lee et al., 2015</xref>). The buffer solutions were aerated with 5% CO<sub>2</sub>/balance air (for CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-containing solutions) or nominally CO<sub>2</sub>-free air (for CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>-free solutions) and pH adjusted to 7.40 at 37°C.</p></sec><sec id="s4-4"><title>Immunohistochemistry</title><p>Histological sections were prepared from paraffin-embedded tissue blocks and immunohistochemically stained on a BenchMark ULTRA automated staining system (Roche Diagnostics, Indianapolis, IN). After deparaffinization, slides were heated to 100°C and pretreated using BenchMark ULTRA CC1 conditioning solution (Roche Diagnostics). The slides were then incubated with primary antibody diluted 1:100 in Dako REAL Antibody Diluent (S2022; Agilent Technologies, Inc, Santa Clara, CA) for 32 min. The rabbit anti-NH<sub>2</sub>-terminal NBCn1 antibody was generously provided by Dr Jeppe Praetorius (<xref ref-type="bibr" rid="bib25">Damkier et al., 2006</xref>). The mouse anti-NHE1 antibody (#sc-136239, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2191254">AB_2191254</ext-link>) was from Santa Cruz Biotechnology (Dallas, TX). Finally, endogenous peroxidase activity was inhibited, and bound antibody was detected with the OptiView DAB IHC detection kit (Roche Diagnostics, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2833075">AB_2833075</ext-link>). Stained slides were imaged with a Hamamatsu NanoZoomer S60 digital slide scanner (Japan). Staining intensity was scored by an experienced breast pathologist.</p><p>Information on estrogen receptor, HER2, and Ki67 expression was obtained from the standard diagnostic procedures. We observed a clear distinction between one group with very high estrogen receptor expression (≥90% positive cells) and another group with low estrogen receptor expression (≤15% positive cells) similar to values (median of 10%) previously reported for normal breast tissue (<xref ref-type="bibr" rid="bib44">Oh et al., 2017</xref>). The absence of intermediate expression levels provided a clear and obvious separation between the groups. As previously noted by others (<xref ref-type="bibr" rid="bib22">Coates et al., 2015</xref>), Ki67 expression displays a continuous distribution with no clear separation between groups of high and low expression. The median Ki67 index was 20% in our study cohort as a whole and also in the patient group with estrogen receptor-positive disease (see <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Therefore, we followed the guidelines of the 2015 St Gallen International Expert Consensus recommending a cut-off setting of 30% for identification of patients with a clearly high Ki67 index (<xref ref-type="bibr" rid="bib22">Coates et al., 2015</xref>).</p></sec><sec id="s4-5"><title>Transcript levels and survival data in human breast cancer</title><p>We retrieved seven normalized microarray datasets from studies by van de Vijver and co-workers (<xref ref-type="bibr" rid="bib77">van de Vijver et al., 2002</xref>), Guo and co-workers (<xref ref-type="bibr" rid="bib30">Guo et al., 2005</xref>), Calza and co-workers (<xref ref-type="bibr" rid="bib19">Calza et al., 2006</xref>), and from the Gene Expression Omnibus series: GSE1992 (<xref ref-type="bibr" rid="bib31">Hu et al., 2006</xref>), GSE2034 (<xref ref-type="bibr" rid="bib81">Wang et al., 2005</xref>), GSE11121 (<xref ref-type="bibr" rid="bib63">Schmidt et al., 2008</xref>), and GSE3143 (<xref ref-type="bibr" rid="bib7">Bild et al., 2006</xref>). These studies collectively cover 1457 breast cancer patients with information on our genes of interest. The majority of the studies measure gene expression with multiple probes per gene; and therefore, we collapsed the multiple expression values by gene symbol using the maximum mean probe intensity. Next, we assigned each sample to one of the five well-defined breast cancer molecular subtypes (normal-like, luminal A, luminal B, HER2-enriched, and basal-like) identified in previous studies (<xref ref-type="bibr" rid="bib67">Sørlie et al., 2001</xref>; <xref ref-type="bibr" rid="bib53">Perou et al., 2000</xref>) using the PAM50 Breast Cancer Intrinsic Classifier (<xref ref-type="bibr" rid="bib48">Parker et al., 2009</xref>).</p><p>To conduct a meta-analysis, we cross-sample standardized each dataset separately, and then combined all seven datasets into one expression matrix that was subjected to a second round of cross-sample standardization. We used this standardized expression matrix to compare and test for differential gene expression levels of <italic>CD34</italic>, <italic>ESR1</italic>, <italic>HER2</italic>, <italic>LDHA</italic>, <italic>MKI67</italic>, <italic>PECAM1</italic>, <italic>PGR</italic>, <italic>SLC4A7</italic>, <italic>SLC9A1</italic>, <italic>SLC16A1</italic>, and <italic>SLC16A3</italic> between the five molecular subtypes and for survival analyses. Kaplan-Meier survival curves were constructed for groups with high and low mRNA expression defined by z-scores above 0.5 and below –0.5, respectively. In cases where either the group of high or low mRNA expression included less than 10 deaths, we used z-score cut-off thresholds of 0.3 and –0.3. For z-score calculation, the difference between the raw score and the population mean was divided by the population standard deviation.</p></sec><sec id="s4-6"><title>Statistics</title><p>Data are given as mean ± SEM unless otherwise specified; n equals number of patients (i.e., biological replicates) and experiments were performed one time for each experimental condition. No explicit power calculations were performed. Within the study periods, tissue was sampled from all patients, who fulfilled the inclusion criteria, and allocated to the appropriate groups based on information from the standard diagnostic procedures. The investigators were blinded during the experiments and analyses, as the clinicopathological information was not collected until later. We considered p-values smaller than 0.05 as statistically significant. Acid-base transport activities and steady-state pH<sub>i</sub> values were compared between groups by mixed-effects analyses followed by Sidak’s multiple comparisons test. We compared categorical protein expression levels by χ<sup>2</sup>-tests for trend. mRNA expression data were compared between multiple groups by one-way ANOVA followed by Tukey’s post-test. Relationships between patient age, tumor size, acid-base transport activity, and steady-state pH<sub>i</sub> were tested by Spearman’s correlation analyses. We identified associations between multiple clinical and pathological independent variables and continuous dependent variables based on multiple linear regression analyses, whereas we identified associations with dichotomous and ordered categorical dependent variables using binomial and ordinal logistic regression analyses, respectively. Kaplan-Meier survival curves were compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. We tested pairwise correlations between mRNA expression of acid-base transporters, angiogenic markers, and sex hormone and growth factor receptors based on Pearson and partial correlation analyses. Statistical analyses were performed with GraphPad Prism 9.0.0 (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link>) and IBM SPSS Statistics (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002865">SCR_002865</ext-link>) software.</p></sec><sec id="s4-7"><title>Study approval</title><p>All participants gave written informed consent. The Mid-Jutland regional division of the Danish Committee on Health Research Ethics (M-20100288) and the Danish Data Protection Agency (1-16-02-191-16) approved the procedures for tissue sampling and data handling, respectively.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank doctors and nurses, especially Dr Ida E Holm, at Regionshospitalet Randers for their contribution to tissue collection and pathology evaluation. We thank Jette K Jensen and Karen L Kristensen, Department of Pathology, Regionshospitalet Randers, for expert technical assistance. Funding: This work was financially supported by the Independent Research Fund Denmark (7025-00050B to Boedtkjer), the Novo Nordisk Foundation (NNF18OC0053037 to Boedtkjer), and the Danish Cancer Society (R136-A8670 to Toft).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an inventor on patents covering NBCn1 as target for cancer therapy (EP 3271402).</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: All participants gave written informed consent. The Mid-Jutland regional division of the Danish Committee on Health Research Ethics (M-20100288) and the Danish Data Protection Agency (1-16-02-191-16) approved the procedures for tissue sampling and data handling, respectively.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-68447-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>In order to comply with the ethical approval, we share the human data presented in Figure 1–8 and corresponding figure supplements (data on acid-base transport activity, intracellular pH, and protein expression of transporters linked to clinicopathological information) in de-identified form. Following consultation with the legal team at the Regional Committee on Health Research Ethics, we have generated dataset files where restricted information is grouped in intervals each consisting of no less than five individuals. To provide the reader with the best possible data insight, we also show figure supplements with more detailed and advanced plots of the data and include the corresponding de-identified dataset. The meta analyses presented in Figure 9, 10, and corresponding figure supplements (data on RNA expression linked to patient survival) are based on data that have previously been published by other investigators, as detailed in the manuscript and the dataset list.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Voskuil</surname><given-names>DW</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Peterse</surname><given-names>JL</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Parrish</surname><given-names>M</given-names></name><name><surname>Atsma</surname><given-names>D</given-names></name><name><surname>Witteveen</surname><given-names>A</given-names></name><name><surname>Glas</surname><given-names>A</given-names></name><name><surname>Delahaye</surname><given-names>L</given-names></name><name><surname>van der Velde</surname><given-names>T</given-names></name><name><surname>Bartelink</surname><given-names>H</given-names></name><name><surname>Rodenhuis</surname><given-names>S</given-names></name><name><surname>Rutgers</surname><given-names>ET</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><data-title>A gene-expression signature as a predictor of survival in breast cancer</data-title><source>Budczies J</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="http://bioconductor.org/packages/release/data/experiment/html/cancerdata.html">cancerdata</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Calza</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>P</given-names></name><name><surname>Auer</surname><given-names>G</given-names></name><name><surname>Bjöhle</surname><given-names>J</given-names></name><name><surname>Klaar</surname><given-names>S</given-names></name><name><surname>Kronenwett</surname><given-names>U</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Miller</surname><given-names>L</given-names></name><name><surname>Ploner</surname><given-names>A</given-names></name><name><surname>Smeds</surname><given-names>J</given-names></name><name><surname>Bergh</surname><given-names>J</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><data-title>Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients</data-title><source>Karolinska Institutet</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://www.meb.ki.se/sites/yudpaw/wp-content/uploads/sites/5/papers/Intrinsic_Signature.zip">Intrinsic_Signature.zip</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Klijn</surname><given-names>JGM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sieuwerts</surname><given-names>AM</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Talantov</surname><given-names>D</given-names></name><name><surname>Timmermans</surname><given-names>M</given-names></name><name><surname>van Gelder</surname><given-names>MEM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jatkoe</surname><given-names>T</given-names></name><name><surname>Berns</surname><given-names>EMJJ</given-names></name><name><surname>Atkins</surname><given-names>D</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2006">2006</year><data-title>The molecular portraits of breast tumors are conserved across microarray platforms</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1992">GSE1992</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Klijn</surname><given-names>JGM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sieuwerts</surname><given-names>AM</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Talantov</surname><given-names>D</given-names></name><name><surname>Timmermans</surname><given-names>M</given-names></name><name><surname>van Gelder</surname><given-names>MEM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jatkoe</surname><given-names>T</given-names></name><name><surname>Berns</surname><given-names>EMJJ</given-names></name><name><surname>Atkins</surname><given-names>D</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2005">2005</year><data-title>Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2034">GSE2034</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Böhm</surname><given-names>D</given-names></name><name><surname>von Törne</surname><given-names>C</given-names></name><name><surname>Steiner</surname><given-names>E</given-names></name><name><surname>Puhl</surname><given-names>A</given-names></name><name><surname>Pilch</surname><given-names>H</given-names></name><name><surname>Lehr</surname><given-names>H-A</given-names></name><name><surname>Hengstler</surname><given-names>JG</given-names></name><name><surname>Kölbl</surname><given-names>H</given-names></name><name><surname>Gehrmann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><data-title>The humoral immune system has a key prognostic impact in node-negative breast cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11121">GSE11121</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Bild</surname><given-names>AH</given-names></name><name><surname>Yao</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Potti</surname><given-names>A</given-names></name><name><surname>Chasse</surname><given-names>D</given-names></name><name><surname>Joshi</surname><given-names>MB</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Olson Jr</surname><given-names>JA</given-names></name><name><surname>Marks</surname><given-names>JR</given-names></name><name><surname>Dressman</surname><given-names>HK</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Nevins</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006</year><data-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3143">GSE3143</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aalkjaer</surname> <given-names>C</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Choi</surname> <given-names>I</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cation-coupled bicarbonate transporters</article-title><source>Comprehensive Physiology</source><volume>4</volume><fpage>1605</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1002/cphy.c130005</pub-id><pub-id pub-id-type="pmid">25428855</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acheampong</surname> <given-names>T</given-names></name><name><surname>Kehm</surname> <given-names>RD</given-names></name><name><surname>Terry</surname> <given-names>MB</given-names></name><name><surname>Argov</surname> <given-names>EL</given-names></name><name><surname>Tehranifar</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016</article-title><source>JAMA Network Open</source><volume>3</volume><elocation-id>e2013226</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.13226</pub-id><pub-id pub-id-type="pmid">32804214</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amith</surname> <given-names>SR</given-names></name><name><surname>Fliegel</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Na<sup>+</sup>/H<sup>+</sup> exchanger-mediated hydrogen ion extrusion as a carcinogenic signal in triple-negative breast cancer etiopathogenesis and prospects for its inhibition in therapeutics</article-title><source>Seminars in Cancer Biology</source><volume>43</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.01.004</pub-id><pub-id pub-id-type="pmid">28104391</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ávalos-Moreno</surname> <given-names>M</given-names></name><name><surname>López-Tejada</surname> <given-names>A</given-names></name><name><surname>Blaya-Cánovas</surname> <given-names>JL</given-names></name><name><surname>Cara-Lupiañez</surname> <given-names>FE</given-names></name><name><surname>González-González</surname> <given-names>A</given-names></name><name><surname>Lorente</surname> <given-names>JA</given-names></name><name><surname>Sánchez-Rovira</surname> <given-names>P</given-names></name><name><surname>Granados-Principal</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Drug repurposing for triple-negative breast cancer</article-title><source>Journal of Personalized Medicine</source><volume>10</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.3390/jpm10040200</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beloueche-Babari</surname> <given-names>M</given-names></name><name><surname>Wantuch</surname> <given-names>S</given-names></name><name><surname>Casals Galobart</surname> <given-names>T</given-names></name><name><surname>Koniordou</surname> <given-names>M</given-names></name><name><surname>Parkes</surname> <given-names>HG</given-names></name><name><surname>Arunan</surname> <given-names>V</given-names></name><name><surname>Chung</surname> <given-names>YL</given-names></name><name><surname>Eykyn</surname> <given-names>TR</given-names></name><name><surname>Smith</surname> <given-names>PD</given-names></name><name><surname>Leach</surname> <given-names>MO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy</article-title><source>Cancer Research</source><volume>77</volume><fpage>5913</fpage><lpage>5924</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2686</pub-id><pub-id pub-id-type="pmid">28923861</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname> <given-names>BW</given-names></name><name><surname>Painter</surname> <given-names>WB</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Minamide</surname> <given-names>LS</given-names></name><name><surname>Abe</surname> <given-names>H</given-names></name><name><surname>Bamburg</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Intracellular pH modulation of ADF/cofilin proteins</article-title><source>Cell Motility and the Cytoskeleton</source><volume>47</volume><fpage>319</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1002/1097-0169(200012)47:4&lt;319::AID-CM6&gt;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">11093252</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bild</surname> <given-names>AH</given-names></name><name><surname>Yao</surname> <given-names>G</given-names></name><name><surname>Chang</surname> <given-names>JT</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Potti</surname> <given-names>A</given-names></name><name><surname>Chasse</surname> <given-names>D</given-names></name><name><surname>Joshi</surname> <given-names>MB</given-names></name><name><surname>Harpole</surname> <given-names>D</given-names></name><name><surname>Lancaster</surname> <given-names>JM</given-names></name><name><surname>Berchuck</surname> <given-names>A</given-names></name><name><surname>Olson</surname> <given-names>JA</given-names></name><name><surname>Marks</surname> <given-names>JR</given-names></name><name><surname>Dressman</surname> <given-names>HK</given-names></name><name><surname>West</surname> <given-names>M</given-names></name><name><surname>Nevins</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oncogenic pathway signatures in human cancers as a guide to targeted therapies</article-title><source>Nature</source><volume>439</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature04296</pub-id><pub-id pub-id-type="pmid">16273092</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Praetorius</surname> <given-names>J</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>NBCn1 (slc4a7) mediates the Na<sup>+</sup>-dependent bicarbonate transport important for regulation of intracellular pH in mouse vascular smooth muscle cells</article-title><source>Circulation Research</source><volume>98</volume><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000204750.04971.76</pub-id><pub-id pub-id-type="pmid">16439691</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Bunch</surname> <given-names>L</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy</article-title><source>Current Pharmaceutical Design</source><volume>18</volume><fpage>1345</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.2174/138161212799504830</pub-id><pub-id pub-id-type="pmid">22360557</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Moreira</surname> <given-names>JM</given-names></name><name><surname>Mele</surname> <given-names>M</given-names></name><name><surname>Vahl</surname> <given-names>P</given-names></name><name><surname>Wielenga</surname> <given-names>VT</given-names></name><name><surname>Christiansen</surname> <given-names>PM</given-names></name><name><surname>Jensen</surname> <given-names>VE</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Contribution of Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup>-cotransport to cellular pH control in human breast cancer: a role for the breast cancer susceptibility locus NBCn1 (SLC4A7)</article-title><source>International Journal of Cancer</source><volume>132</volume><fpage>1288</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1002/ijc.27782</pub-id><pub-id pub-id-type="pmid">22907202</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Bentzon</surname> <given-names>JF</given-names></name><name><surname>Dam</surname> <given-names>VS</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Na<sup>+</sup>, HCO<sub>3</sub><sup>–</sup>-cotransporter NBCn1 increases pH<sub>i</sub> gradients, filopodia, and migration of smooth muscle cells and promotes arterial remodelling</article-title><source>Cardiovascular Research</source><volume>111</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw079</pub-id><pub-id pub-id-type="pmid">27076468</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Na<sup>+</sup>,HCO<sub>3</sub><sup>−</sup> cotransporter NBCn1 accelerates breast carcinogenesis</article-title><source>Cancer and Metastasis Reviews</source><volume>38</volume><fpage>165</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s10555-019-09784-7</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Insulin inhibits Na<sup>+</sup>/H<sup>+</sup> exchange in vascular smooth muscle and endothelial cells in situ: involvement of H<sub>2</sub>O<sub>2 </sub>and tyrosine phosphatase SHP-2</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>296</volume><fpage>H247</fpage><lpage>H255</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00725.2008</pub-id><pub-id pub-id-type="pmid">19036852</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intracellular pH in the resistance vasculature: regulation and functional implications</article-title><source>Journal of Vascular Research</source><volume>49</volume><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1159/000341235</pub-id><pub-id pub-id-type="pmid">22907294</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Acid-base transporters modulate cell migration, growth and proliferation: implications for structure development and remodeling of resistance arteries?</article-title><source>Trends in Cardiovascular Medicine</source><volume>23</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2012.09.001</pub-id><pub-id pub-id-type="pmid">23266155</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The acidic tumor microenvironment as a driver of cancer</article-title><source>Annual Review of Physiology</source><volume>82</volume><fpage>103</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021119-034627</pub-id><pub-id pub-id-type="pmid">31730395</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonde</surname> <given-names>L</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extracellular acidosis and very low [Na<sup>+</sup>] inhibit NBCn1- and NHE1-mediated net acid extrusion from mouse vascular smooth muscle cells</article-title><source>Acta Physiologica</source><volume>221</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1111/apha.12877</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boron</surname> <given-names>WF</given-names></name><name><surname>De Weer</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Intracellular pH transients in squid giant axons caused by CO<sub>2</sub>, NH<sub>3</sub>, and metabolic inhibitors</article-title><source>Journal of General Physiology</source><volume>67</volume><fpage>91</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1085/jgp.67.1.91</pub-id><pub-id pub-id-type="pmid">1460</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calza</surname> <given-names>S</given-names></name><name><surname>Hall</surname> <given-names>P</given-names></name><name><surname>Auer</surname> <given-names>G</given-names></name><name><surname>Bjöhle</surname> <given-names>J</given-names></name><name><surname>Klaar</surname> <given-names>S</given-names></name><name><surname>Kronenwett</surname> <given-names>U</given-names></name><name><surname>Liu</surname> <given-names>ET</given-names></name><name><surname>Miller</surname> <given-names>L</given-names></name><name><surname>Ploner</surname> <given-names>A</given-names></name><name><surname>Smeds</surname> <given-names>J</given-names></name><name><surname>Bergh</surname> <given-names>J</given-names></name><name><surname>Pawitan</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients</article-title><source>Breast Cancer Research</source><volume>8</volume><elocation-id>R34</elocation-id><pub-id pub-id-type="doi">10.1186/bcr1517</pub-id><pub-id pub-id-type="pmid">16846532</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassim</surname> <given-names>S</given-names></name><name><surname>Pouyssegur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor microenvironment: a metabolic player that shapes the immune response</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21010157</pub-id><pub-id pub-id-type="pmid">31881671</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>I</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name><name><surname>Boulpaep</surname> <given-names>EL</given-names></name><name><surname>Boron</surname> <given-names>WF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>An electroneutral sodium/bicarbonate cotransporter NBCn1 and associated sodium channel</article-title><source>Nature</source><volume>405</volume><fpage>571</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/35014615</pub-id><pub-id pub-id-type="pmid">10850716</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname> <given-names>AS</given-names></name><name><surname>Winer</surname> <given-names>EP</given-names></name><name><surname>Goldhirsch</surname> <given-names>A</given-names></name><name><surname>Gelber</surname> <given-names>RD</given-names></name><name><surname>Gnant</surname> <given-names>M</given-names></name><name><surname>Piccart-Gebhart</surname> <given-names>M</given-names></name><name><surname>Thürlimann</surname> <given-names>B</given-names></name><name><surname>Senn</surname> <given-names>HJ</given-names></name><collab>Panel Members</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Tailoring therapies--improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015</article-title><source>Annals of Oncology</source><volume>26</volume><fpage>1533</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv221</pub-id><pub-id pub-id-type="pmid">25939896</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connell</surname> <given-names>CM</given-names></name><name><surname>Doherty</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Activating HER2 mutations as emerging targets in multiple solid cancers</article-title><source>ESMO Open</source><volume>2</volume><elocation-id>e000279</elocation-id><pub-id pub-id-type="doi">10.1136/esmoopen-2017-000279</pub-id><pub-id pub-id-type="pmid">29209536</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Bai</surname> <given-names>Z</given-names></name><name><surname>Yang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Zhan</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Breast cancer intrinsic subtype classification, clinical use and future trends</article-title><source>American Journal of Cancer Research</source><volume>5</volume><fpage>2929</fpage><lpage>2943</lpage><pub-id pub-id-type="pmid">26693050</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damkier</surname> <given-names>HH</given-names></name><name><surname>Nielsen</surname> <given-names>S</given-names></name><name><surname>Praetorius</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An anti-NH<sub>2</sub>-terminal antibody localizes NBCn1 to heart endothelia and skeletal and vascular smooth muscle cells</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>290</volume><fpage>H172</fpage><lpage>H180</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00713.2005</pub-id><pub-id pub-id-type="pmid">16126812</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danielsen</surname> <given-names>AA</given-names></name><name><surname>Parker</surname> <given-names>MD</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Boron</surname> <given-names>WF</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Splice cassette II of Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporter NBCn1 (slc4a7) interacts with calcineurin A: implications for transporter activity and intracellular pH control during rat artery contractions</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>8146</fpage><lpage>8155</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.455386</pub-id><pub-id pub-id-type="pmid">23382378</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flinck</surname> <given-names>M</given-names></name><name><surname>Kramer</surname> <given-names>SH</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Roles of pH in control of cell proliferation</article-title><source>Acta Physiologica</source><volume>223</volume><elocation-id>e13068</elocation-id><pub-id pub-id-type="doi">10.1111/apha.13068</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamallo</surname> <given-names>C</given-names></name><name><surname>Palacios</surname> <given-names>J</given-names></name><name><surname>Suarez</surname> <given-names>A</given-names></name><name><surname>Pizarro</surname> <given-names>A</given-names></name><name><surname>Navarro</surname> <given-names>P</given-names></name><name><surname>Quintanilla</surname> <given-names>M</given-names></name><name><surname>Cano</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma</article-title><source>The American Journal of Pathology</source><volume>142</volume><fpage>987</fpage><lpage>993</lpage><pub-id pub-id-type="pmid">7682767</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Friess</surname> <given-names>H</given-names></name><name><surname>Graber</surname> <given-names>HU</given-names></name><name><surname>Kashiwagi</surname> <given-names>M</given-names></name><name><surname>Zimmermann</surname> <given-names>A</given-names></name><name><surname>Korc</surname> <given-names>M</given-names></name><name><surname>Büchler</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases</article-title><source>Cancer Research</source><volume>56</volume><fpage>4876</fpage><lpage>4880</lpage><pub-id pub-id-type="pmid">8895737</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Topol</surname> <given-names>EJ</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Rao</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Towards precise classification of cancers based on robust gene functional expression profiles</article-title><source>BMC Bioinformatics</source><volume>6</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-6-58</pub-id><pub-id pub-id-type="pmid">15774002</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Fan</surname> <given-names>C</given-names></name><name><surname>Oh</surname> <given-names>DS</given-names></name><name><surname>Marron</surname> <given-names>JS</given-names></name><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Qaqish</surname> <given-names>BF</given-names></name><name><surname>Livasy</surname> <given-names>C</given-names></name><name><surname>Carey</surname> <given-names>LA</given-names></name><name><surname>Reynolds</surname> <given-names>E</given-names></name><name><surname>Dressler</surname> <given-names>L</given-names></name><name><surname>Nobel</surname> <given-names>A</given-names></name><name><surname>Parker</surname> <given-names>J</given-names></name><name><surname>Ewend</surname> <given-names>MG</given-names></name><name><surname>Sawyer</surname> <given-names>LR</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Nanda</surname> <given-names>R</given-names></name><name><surname>Tretiakova</surname> <given-names>M</given-names></name><name><surname>Ruiz Orrico</surname> <given-names>A</given-names></name><name><surname>Dreher</surname> <given-names>D</given-names></name><name><surname>Palazzo</surname> <given-names>JP</given-names></name><name><surname>Perreard</surname> <given-names>L</given-names></name><name><surname>Nelson</surname> <given-names>E</given-names></name><name><surname>Mone</surname> <given-names>M</given-names></name><name><surname>Hansen</surname> <given-names>H</given-names></name><name><surname>Mullins</surname> <given-names>M</given-names></name><name><surname>Quackenbush</surname> <given-names>JF</given-names></name><name><surname>Ellis</surname> <given-names>MJ</given-names></name><name><surname>Olopade</surname> <given-names>OI</given-names></name><name><surname>Bernard</surname> <given-names>PS</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The molecular portraits of breast tumors are conserved across microarray platforms</article-title><source>BMC Genomics</source><volume>7</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-7-96</pub-id><pub-id pub-id-type="pmid">16643655</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulikova</surname> <given-names>A</given-names></name><name><surname>Vaughan-Jones</surname> <given-names>RD</given-names></name><name><surname>Swietach</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dual role of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup> buffer in the regulation of intracellular pH of three-dimensional tumor growths</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>13815</fpage><lpage>13826</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.219899</pub-id><pub-id pub-id-type="pmid">21345798</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname> <given-names>S</given-names></name><name><surname>Shin</surname> <given-names>DM</given-names></name><name><surname>Hong</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Protective role of IRBIT on sodium bicarbonate cotransporter-n1 for migratory cancer cells</article-title><source>Pharmaceutics</source><volume>12</volume><elocation-id>816</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12090816</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname> <given-names>A</given-names></name><name><surname>Stroup</surname> <given-names>AM</given-names></name><name><surname>Paddock</surname> <given-names>LE</given-names></name><name><surname>Hill</surname> <given-names>SM</given-names></name><name><surname>Plascak</surname> <given-names>JJ</given-names></name><name><surname>Llanos</surname> <given-names>AAM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Breast cancer incidence and mortality by molecular subtype: statewide age and racial/ethnic disparities in New Jersey</article-title><source>Cancer Health Disparities</source><volume>3</volume><fpage>e1</fpage><lpage>e17</lpage><pub-id pub-id-type="doi">10.9777/chd.2019.1012</pub-id><pub-id pub-id-type="pmid">31440744</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname> <given-names>AM</given-names></name><name><surname>Krogsgaard-Larsen</surname> <given-names>N</given-names></name><name><surname>Lauritzen</surname> <given-names>G</given-names></name><name><surname>Olesen</surname> <given-names>CW</given-names></name><name><surname>Honoré Hansen</surname> <given-names>S</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name><name><surname>Bunch</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Gram-scale solution-phase synthesis of selective sodium bicarbonate co-transport inhibitor S0859: in vitro efficacy studies in breast cancer cells</article-title><source>ChemMedChem</source><volume>7</volume><fpage>1808</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201200335</pub-id><pub-id pub-id-type="pmid">22927258</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname> <given-names>G</given-names></name><name><surname>Jensen</surname> <given-names>MB</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Dybboe</surname> <given-names>R</given-names></name><name><surname>Aalkjaer</surname> <given-names>C</given-names></name><name><surname>Nylandsted</surname> <given-names>J</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>NBCn1 and NHE1 expression and activity in ΔNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pH<sub>i</sub> regulation and chemotherapy resistance</article-title><source>Experimental Cell Research</source><volume>316</volume><fpage>2538</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2010.06.005</pub-id><pub-id pub-id-type="pmid">20542029</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname> <given-names>G</given-names></name><name><surname>Stock</surname> <given-names>CM</given-names></name><name><surname>Lemaire</surname> <given-names>J</given-names></name><name><surname>Lund</surname> <given-names>SF</given-names></name><name><surname>Jensen</surname> <given-names>MF</given-names></name><name><surname>Damsgaard</surname> <given-names>B</given-names></name><name><surname>Petersen</surname> <given-names>KS</given-names></name><name><surname>Wiwel</surname> <given-names>M</given-names></name><name><surname>Rønnov-Jessen</surname> <given-names>L</given-names></name><name><surname>Schwab</surname> <given-names>A</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1, but not the Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2</article-title><source>Cancer Letters</source><volume>317</volume><fpage>172</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.11.023</pub-id><pub-id pub-id-type="pmid">22120673</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Mele</surname> <given-names>M</given-names></name><name><surname>Vahl</surname> <given-names>P</given-names></name><name><surname>Christiansen</surname> <given-names>PM</given-names></name><name><surname>Jensen</surname> <given-names>VE</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup>-cotransport is functionally upregulated during human breast carcinogenesis and required for the inverted pH gradient across the plasma membrane</article-title><source>Pflügers Archiv - European Journal of Physiology</source><volume>467</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1007/s00424-014-1524-0</pub-id><pub-id pub-id-type="pmid">24788003</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Axelsen</surname> <given-names>TV</given-names></name><name><surname>Andersen</surname> <given-names>AP</given-names></name><name><surname>Vahl</surname> <given-names>P</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disrupting Na⁺, HCO<sub>3</sub>⁻-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development</article-title><source>Oncogene</source><volume>35</volume><fpage>2112</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.273</pub-id><pub-id pub-id-type="pmid">26212013</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Axelsen</surname> <given-names>TV</given-names></name><name><surname>Jessen</surname> <given-names>N</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name><name><surname>Vahl</surname> <given-names>P</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup>-cotransporter NBCn1 (Slc4a7) accelerates ErbB2-induced breast cancer development and tumor growth in mice</article-title><source>Oncogene</source><volume>37</volume><fpage>5569</fpage><lpage>5584</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0353-6</pub-id><pub-id pub-id-type="pmid">29907770</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname> <given-names>SY</given-names></name><name><surname>Chang</surname> <given-names>MK</given-names></name><name><surname>Chua</surname> <given-names>CS</given-names></name><name><surname>Kumar</surname> <given-names>AP</given-names></name><name><surname>Pervaiz</surname> <given-names>S</given-names></name><name><surname>Clement</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NHE-1: a promising target for novel anti-cancer therapeutics</article-title><source>Current Pharmaceutical Design</source><volume>18</volume><fpage>1372</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.2174/138161212799504885</pub-id><pub-id pub-id-type="pmid">22360552</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mentzer</surname> <given-names>RM</given-names></name><name><surname>Bartels</surname> <given-names>C</given-names></name><name><surname>Bolli</surname> <given-names>R</given-names></name><name><surname>Boyce</surname> <given-names>S</given-names></name><name><surname>Buckberg</surname> <given-names>GD</given-names></name><name><surname>Chaitman</surname> <given-names>B</given-names></name><name><surname>Haverich</surname> <given-names>A</given-names></name><name><surname>Knight</surname> <given-names>J</given-names></name><name><surname>Menasché</surname> <given-names>P</given-names></name><name><surname>Myers</surname> <given-names>ML</given-names></name><name><surname>Nicolau</surname> <given-names>J</given-names></name><name><surname>Simoons</surname> <given-names>M</given-names></name><name><surname>Thulin</surname> <given-names>L</given-names></name><name><surname>Weisel</surname> <given-names>RD</given-names></name><collab>EXPEDITION Study Investigators</collab></person-group><year iso-8601-date="2008">2008</year><article-title>Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study</article-title><source>The Annals of Thoracic Surgery</source><volume>85</volume><fpage>1261</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.10.054</pub-id><pub-id pub-id-type="pmid">18355507</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname> <given-names>SS</given-names></name><name><surname>Pardee</surname> <given-names>AB</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Intracellular pH is increased after transformation of chinese hamster embryo fibroblasts</article-title><source>PNAS</source><volume>84</volume><fpage>2766</fpage><lpage>2770</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.9.2766</pub-id><pub-id pub-id-type="pmid">3554247</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>H</given-names></name><name><surname>Eliassen</surname> <given-names>AH</given-names></name><name><surname>Beck</surname> <given-names>AH</given-names></name><name><surname>Rosner</surname> <given-names>B</given-names></name><name><surname>Schnitt</surname> <given-names>SJ</given-names></name><name><surname>Collins</surname> <given-names>LC</given-names></name><name><surname>Connolly</surname> <given-names>JL</given-names></name><name><surname>Montaser-Kouhsari</surname> <given-names>L</given-names></name><name><surname>Willett</surname> <given-names>WC</given-names></name><name><surname>Tamimi</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue</article-title><source>Npj Breast Cancer</source><volume>3</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1038/s41523-017-0041-7</pub-id><pub-id pub-id-type="pmid">28979927</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname> <given-names>CW</given-names></name><name><surname>Vogensen</surname> <given-names>J</given-names></name><name><surname>Axholm</surname> <given-names>I</given-names></name><name><surname>Severin</surname> <given-names>M</given-names></name><name><surname>Schnipper</surname> <given-names>J</given-names></name><name><surname>Pedersen</surname> <given-names>IS</given-names></name><name><surname>von Stemann</surname> <given-names>JH</given-names></name><name><surname>Schrøder</surname> <given-names>JM</given-names></name><name><surname>Christensen</surname> <given-names>DP</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Trafficking, localization and degradation of the Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup> co-transporter NBCn1 in kidney and breast epithelial cells</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>7435</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-25059-7</pub-id><pub-id pub-id-type="pmid">29743600</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onitilo</surname> <given-names>AA</given-names></name><name><surname>Engel</surname> <given-names>JM</given-names></name><name><surname>Stankowski</surname> <given-names>RV</given-names></name><name><surname>Doi</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy</article-title><source>Clinical Medicine &amp; Research</source><volume>13</volume><fpage>65</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3121/cmr.2014.1245</pub-id><pub-id pub-id-type="pmid">25487237</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname> <given-names>K</given-names></name><name><surname>Baliga</surname> <given-names>P</given-names></name><name><surname>Shrestha</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>E-cadherin expression: a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies</article-title><source>Journal of Clinical and Diagnostic Research</source><volume>7</volume><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2013/5755.2954</pub-id><pub-id pub-id-type="pmid">23814724</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname> <given-names>JS</given-names></name><name><surname>Mullins</surname> <given-names>M</given-names></name><name><surname>Cheang</surname> <given-names>MC</given-names></name><name><surname>Leung</surname> <given-names>S</given-names></name><name><surname>Voduc</surname> <given-names>D</given-names></name><name><surname>Vickery</surname> <given-names>T</given-names></name><name><surname>Davies</surname> <given-names>S</given-names></name><name><surname>Fauron</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>X</given-names></name><name><surname>Hu</surname> <given-names>Z</given-names></name><name><surname>Quackenbush</surname> <given-names>JF</given-names></name><name><surname>Stijleman</surname> <given-names>IJ</given-names></name><name><surname>Palazzo</surname> <given-names>J</given-names></name><name><surname>Marron</surname> <given-names>JS</given-names></name><name><surname>Nobel</surname> <given-names>AB</given-names></name><name><surname>Mardis</surname> <given-names>E</given-names></name><name><surname>Nielsen</surname> <given-names>TO</given-names></name><name><surname>Ellis</surname> <given-names>MJ</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Bernard</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title><source>Journal of Clinical Oncology</source><volume>27</volume><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.1370</pub-id><pub-id pub-id-type="pmid">19204204</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname> <given-names>SK</given-names></name><name><surname>Chiche</surname> <given-names>J</given-names></name><name><surname>Pouysségur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Disrupting proton dynamics and energy metabolism for cancer therapy</article-title><source>Nature Reviews Cancer</source><volume>13</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/nrc3579</pub-id><pub-id pub-id-type="pmid">23969692</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname> <given-names>SK</given-names></name><name><surname>Cormerais</surname> <given-names>Y</given-names></name><name><surname>Pouysségur</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hypoxia and cellular metabolism in tumour pathophysiology</article-title><source>The Journal of Physiology</source><volume>595</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1113/JP273309</pub-id><pub-id pub-id-type="pmid">28074546</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 in stress-induced signal transduction: implications for cell proliferation and cell death</article-title><source>Pflügers Archiv - European Journal of Physiology</source><volume>452</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1007/s00424-006-0044-y</pub-id><pub-id pub-id-type="pmid">16586098</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Escuredo</surname> <given-names>J</given-names></name><name><surname>Van Hée</surname> <given-names>VF</given-names></name><name><surname>Sboarina</surname> <given-names>M</given-names></name><name><surname>Falces</surname> <given-names>J</given-names></name><name><surname>Payen</surname> <given-names>VL</given-names></name><name><surname>Pellerin</surname> <given-names>L</given-names></name><name><surname>Sonveaux</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Monocarboxylate transporters in the brain and in cancer</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</source><volume>1863</volume><fpage>2481</fpage><lpage>2497</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.03.013</pub-id><pub-id pub-id-type="pmid">26993058</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Sørlie</surname> <given-names>T</given-names></name><name><surname>Eisen</surname> <given-names>MB</given-names></name><name><surname>van de Rijn</surname> <given-names>M</given-names></name><name><surname>Jeffrey</surname> <given-names>SS</given-names></name><name><surname>Rees</surname> <given-names>CA</given-names></name><name><surname>Pollack</surname> <given-names>JR</given-names></name><name><surname>Ross</surname> <given-names>DT</given-names></name><name><surname>Johnsen</surname> <given-names>H</given-names></name><name><surname>Akslen</surname> <given-names>LA</given-names></name><name><surname>Fluge</surname> <given-names>O</given-names></name><name><surname>Pergamenschikov</surname> <given-names>A</given-names></name><name><surname>Williams</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>SX</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name><name><surname>Brown</surname> <given-names>PO</given-names></name><name><surname>Botstein</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persi</surname> <given-names>E</given-names></name><name><surname>Wolf</surname> <given-names>YI</given-names></name><name><surname>Horn</surname> <given-names>D</given-names></name><name><surname>Ruppin</surname> <given-names>E</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Gatenby</surname> <given-names>RA</given-names></name><name><surname>Gillies</surname> <given-names>RJ</given-names></name><name><surname>Koonin</surname> <given-names>EV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mutation-selection balance and compensatory mechanisms in tumour evolution</article-title><source>Nature Reviews Genetics</source><volume>22</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-00299-4</pub-id><pub-id pub-id-type="pmid">33257848</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname> <given-names>BJ</given-names></name><name><surname>Zierler-Gould</surname> <given-names>KM</given-names></name><name><surname>Kühne</surname> <given-names>R</given-names></name><name><surname>Weeds</surname> <given-names>AG</given-names></name><name><surname>Ball</surname> <given-names>LJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Solution structure of human cofilin: actin binding, pH sensitivity, and relationship to actin-depolymerizing factor</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>4840</fpage><lpage>4848</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310148200</pub-id><pub-id pub-id-type="pmid">14627701</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouysségur</surname> <given-names>J</given-names></name><name><surname>Franchi</surname> <given-names>A</given-names></name><name><surname>L'Allemain</surname> <given-names>G</given-names></name><name><surname>Paris</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts</article-title><source>FEBS Letters</source><volume>190</volume><fpage>115</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(85)80439-7</pub-id><pub-id pub-id-type="pmid">4043390</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakha</surname> <given-names>EA</given-names></name><name><surname>Reis-Filho</surname> <given-names>JS</given-names></name><name><surname>Baehner</surname> <given-names>F</given-names></name><name><surname>Dabbs</surname> <given-names>DJ</given-names></name><name><surname>Decker</surname> <given-names>T</given-names></name><name><surname>Eusebi</surname> <given-names>V</given-names></name><name><surname>Fox</surname> <given-names>SB</given-names></name><name><surname>Ichihara</surname> <given-names>S</given-names></name><name><surname>Jacquemier</surname> <given-names>J</given-names></name><name><surname>Lakhani</surname> <given-names>SR</given-names></name><name><surname>Palacios</surname> <given-names>J</given-names></name><name><surname>Richardson</surname> <given-names>AL</given-names></name><name><surname>Schnitt</surname> <given-names>SJ</given-names></name><name><surname>Schmitt</surname> <given-names>FC</given-names></name><name><surname>Tan</surname> <given-names>PH</given-names></name><name><surname>Tse</surname> <given-names>GM</given-names></name><name><surname>Badve</surname> <given-names>S</given-names></name><name><surname>Ellis</surname> <given-names>IO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Breast cancer prognostic classification in the molecular era: the role of histological grade</article-title><source>Breast Cancer Research</source><volume>12</volume><elocation-id>207</elocation-id><pub-id pub-id-type="doi">10.1186/bcr2607</pub-id><pub-id pub-id-type="pmid">20804570</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riemann</surname> <given-names>A</given-names></name><name><surname>Rauschner</surname> <given-names>M</given-names></name><name><surname>Gießelmann</surname> <given-names>M</given-names></name><name><surname>Reime</surname> <given-names>S</given-names></name><name><surname>Haupt</surname> <given-names>V</given-names></name><name><surname>Thews</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Extracellular acidosis modulates the expression of Epithelial-Mesenchymal transition (EMT) Markers and adhesion of epithelial and tumor cells</article-title><source>Neoplasia</source><volume>21</volume><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2019.03.004</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rofstad</surname> <given-names>EK</given-names></name><name><surname>Mathiesen</surname> <given-names>B</given-names></name><name><surname>Kindem</surname> <given-names>K</given-names></name><name><surname>Galappathi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice</article-title><source>Cancer Research</source><volume>66</volume><fpage>6699</fpage><lpage>6707</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0983</pub-id><pub-id pub-id-type="pmid">16818644</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolver</surname> <given-names>MG</given-names></name><name><surname>Elingaard-Larsen</surname> <given-names>LO</given-names></name><name><surname>Andersen</surname> <given-names>AP</given-names></name><name><surname>Counillon</surname> <given-names>L</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pyrazine ring-based Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) inhibitors potently inhibit cancer cell growth in 3D culture, independent of NHE1</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>5800</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-62430-z</pub-id><pub-id pub-id-type="pmid">32242030</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname> <given-names>MF</given-names></name><name><surname>Fulton</surname> <given-names>CM</given-names></name><name><surname>Boron</surname> <given-names>WF</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The SLC4 family of HCO<sub>3</sub><sup>–</sup> transporters</article-title><source>Pflugers Archiv - European Journal of Physiology</source><volume>447</volume><fpage>495</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1007/s00424-003-1180-2</pub-id><pub-id pub-id-type="pmid">14722772</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname> <given-names>A</given-names></name><name><surname>Boron</surname> <given-names>WF</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Intracellular pH</article-title><source>Physiological Reviews</source><volume>61</volume><fpage>296</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1152/physrev.1981.61.2.296</pub-id><pub-id pub-id-type="pmid">7012859</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>M</given-names></name><name><surname>Böhm</surname> <given-names>D</given-names></name><name><surname>von Törne</surname> <given-names>C</given-names></name><name><surname>Steiner</surname> <given-names>E</given-names></name><name><surname>Puhl</surname> <given-names>A</given-names></name><name><surname>Pilch</surname> <given-names>H</given-names></name><name><surname>Lehr</surname> <given-names>HA</given-names></name><name><surname>Hengstler</surname> <given-names>JG</given-names></name><name><surname>Kölbl</surname> <given-names>H</given-names></name><name><surname>Gehrmann</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The humoral immune system has a key prognostic impact in node-negative breast cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>5405</fpage><lpage>5413</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5206</pub-id><pub-id pub-id-type="pmid">18593943</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname> <given-names>A</given-names></name><name><surname>Fabian</surname> <given-names>A</given-names></name><name><surname>Hanley</surname> <given-names>PJ</given-names></name><name><surname>Stock</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of ion channels and transporters in cell migration</article-title><source>Physiological Reviews</source><volume>92</volume><fpage>1865</fpage><lpage>1913</lpage><pub-id pub-id-type="doi">10.1152/physrev.00018.2011</pub-id><pub-id pub-id-type="pmid">23073633</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shyamala</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Roles of estrogen and progesterone in normal mammary gland development insights from progesterone receptor null mutant mice and in situ localization of receptor</article-title><source>Trends in Endocrinology and Metabolism: TEM</source><volume>8</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/s1043-2760(96)00207-x</pub-id><pub-id pub-id-type="pmid">18406784</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>SC</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Learning therapeutic lessons from metastasis suppressor proteins</article-title><source>Nature Reviews Cancer</source><volume>9</volume><fpage>253</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc2594</pub-id><pub-id pub-id-type="pmid">19242414</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sørlie</surname> <given-names>T</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name><name><surname>Tibshirani</surname> <given-names>R</given-names></name><name><surname>Aas</surname> <given-names>T</given-names></name><name><surname>Geisler</surname> <given-names>S</given-names></name><name><surname>Johnsen</surname> <given-names>H</given-names></name><name><surname>Hastie</surname> <given-names>T</given-names></name><name><surname>Eisen</surname> <given-names>MB</given-names></name><name><surname>van de Rijn</surname> <given-names>M</given-names></name><name><surname>Jeffrey</surname> <given-names>SS</given-names></name><name><surname>Thorsen</surname> <given-names>T</given-names></name><name><surname>Quist</surname> <given-names>H</given-names></name><name><surname>Matese</surname> <given-names>JC</given-names></name><name><surname>Brown</surname> <given-names>PO</given-names></name><name><surname>Botstein</surname> <given-names>D</given-names></name><name><surname>Lønning</surname> <given-names>PE</given-names></name><name><surname>Børresen-Dale</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>PNAS</source><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><pub-id pub-id-type="pmid">11553815</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinkamp</surname> <given-names>A-D</given-names></name><name><surname>Seling</surname> <given-names>N</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name><name><surname>Bolm</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthesis of <italic>N</italic>-cyano-substituted sulfilimine and sulfoximine derivatives of S0859 and their biological evaluatio<italic>n</italic> as sodium bicarbonate co-transport inhibitors</article-title><source>MedChemComm</source><volume>6</volume><fpage>2163</fpage><lpage>2169</lpage><pub-id pub-id-type="doi">10.1039/C5MD00367A</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname> <given-names>C</given-names></name><name><surname>Gassner</surname> <given-names>B</given-names></name><name><surname>Hauck</surname> <given-names>CR</given-names></name><name><surname>Arnold</surname> <given-names>H</given-names></name><name><surname>Mally</surname> <given-names>S</given-names></name><name><surname>Eble</surname> <given-names>JA</given-names></name><name><surname>Dieterich</surname> <given-names>P</given-names></name><name><surname>Schwab</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Migration of human melanoma cells depends on extracellular pH and Na<sup>+</sup>/H<sup>+</sup> exchange</article-title><source>The Journal of Physiology</source><volume>567</volume><fpage>225</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2005.088344</pub-id><pub-id pub-id-type="pmid">15946960</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname> <given-names>C</given-names></name><name><surname>Mueller</surname> <given-names>M</given-names></name><name><surname>Kraehling</surname> <given-names>H</given-names></name><name><surname>Mally</surname> <given-names>S</given-names></name><name><surname>Noël</surname> <given-names>J</given-names></name><name><surname>Eder</surname> <given-names>C</given-names></name><name><surname>Schwab</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>pH nanoenvironment at the surface of single melanoma cells</article-title><source>Cellular Physiology and Biochemistry</source><volume>20</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1159/000107550</pub-id><pub-id pub-id-type="pmid">17762194</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stock</surname> <given-names>C</given-names></name><name><surname>Pedersen</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Roles of pH and the Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1 in cancer: from cell biology and animal models to an emerging translational perspective?</article-title><source>Seminars in Cancer Biology</source><volume>43</volume><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2016.12.001</pub-id><pub-id pub-id-type="pmid">28007556</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stransky</surname> <given-names>L</given-names></name><name><surname>Cotter</surname> <given-names>K</given-names></name><name><surname>Forgac</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The function of V-ATPases in cancer</article-title><source>Physiological Reviews</source><volume>96</volume><fpage>1071</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1152/physrev.00035.2015</pub-id><pub-id pub-id-type="pmid">27335445</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname> <given-names>A</given-names></name><name><surname>Maeda</surname> <given-names>T</given-names></name><name><surname>Baba</surname> <given-names>Y</given-names></name><name><surname>Shimamura</surname> <given-names>K</given-names></name><name><surname>Kato</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model</article-title><source>Cancer Cell International</source><volume>14</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/s12935-014-0129-1</pub-id><pub-id pub-id-type="pmid">25493076</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>JA</given-names></name><name><surname>Buchsbaum</surname> <given-names>RN</given-names></name><name><surname>Zimniak</surname> <given-names>A</given-names></name><name><surname>Racker</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Intracellular pH measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ</article-title><source>Biochemistry</source><volume>18</volume><fpage>2210</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1021/bi00578a012</pub-id><pub-id pub-id-type="pmid">36128</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>M</given-names></name><name><surname>Kelly</surname> <given-names>ED</given-names></name><name><surname>Abraham</surname> <given-names>J</given-names></name><name><surname>Kruse</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease</article-title><source>Seminars in Oncology</source><volume>46</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2019.03.002</pub-id><pub-id pub-id-type="pmid">31239068</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valla</surname> <given-names>M</given-names></name><name><surname>Vatten</surname> <given-names>LJ</given-names></name><name><surname>Engstrøm</surname> <given-names>MJ</given-names></name><name><surname>Haugen</surname> <given-names>OA</given-names></name><name><surname>Akslen</surname> <given-names>LA</given-names></name><name><surname>Bjørngaard</surname> <given-names>JH</given-names></name><name><surname>Hagen</surname> <given-names>AI</given-names></name><name><surname>Ytterhus</surname> <given-names>B</given-names></name><name><surname>Bofin</surname> <given-names>AM</given-names></name><name><surname>Opdahl</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences</article-title><source>Cancer Epidemiology Biomarkers &amp; Prevention</source><volume>25</volume><fpage>1625</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0427</pub-id><pub-id pub-id-type="pmid">27672056</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Vijver</surname> <given-names>MJ</given-names></name><name><surname>He</surname> <given-names>YD</given-names></name><name><surname>van't Veer</surname> <given-names>LJ</given-names></name><name><surname>Dai</surname> <given-names>H</given-names></name><name><surname>Hart</surname> <given-names>AA</given-names></name><name><surname>Voskuil</surname> <given-names>DW</given-names></name><name><surname>Schreiber</surname> <given-names>GJ</given-names></name><name><surname>Peterse</surname> <given-names>JL</given-names></name><name><surname>Roberts</surname> <given-names>C</given-names></name><name><surname>Marton</surname> <given-names>MJ</given-names></name><name><surname>Parrish</surname> <given-names>M</given-names></name><name><surname>Atsma</surname> <given-names>D</given-names></name><name><surname>Witteveen</surname> <given-names>A</given-names></name><name><surname>Glas</surname> <given-names>A</given-names></name><name><surname>Delahaye</surname> <given-names>L</given-names></name><name><surname>van der Velde</surname> <given-names>T</given-names></name><name><surname>Bartelink</surname> <given-names>H</given-names></name><name><surname>Rodenhuis</surname> <given-names>S</given-names></name><name><surname>Rutgers</surname> <given-names>ET</given-names></name><name><surname>Friend</surname> <given-names>SH</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title><source>New England Journal of Medicine</source><volume>347</volume><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id><pub-id pub-id-type="pmid">12490681</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Deurzen</surname> <given-names>CH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Predictors of surgical margin following breast-conserving surgery: a large population-based cohort study</article-title><source>Annals of Surgical Oncology</source><volume>23</volume><fpage>627</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5532-5</pub-id><pub-id pub-id-type="pmid">27590331</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaupel</surname> <given-names>P</given-names></name><name><surname>Kallinowski</surname> <given-names>F</given-names></name><name><surname>Okunieff</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review</article-title><source>Cancer Research</source><volume>49</volume><fpage>6449</fpage><lpage>6465</lpage></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname> <given-names>NCS</given-names></name><name><surname>Dreyer</surname> <given-names>T</given-names></name><name><surname>Henningsen</surname> <given-names>MB</given-names></name><name><surname>Vahl</surname> <given-names>P</given-names></name><name><surname>Honoré</surname> <given-names>B</given-names></name><name><surname>Boedtkjer</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting the acidic tumor microenvironment: unexpected pro-neoplastic effects of oral NaHCO<sub>3</sub> therapy in murine breast tissue</article-title><source>Cancers</source><volume>12</volume><elocation-id>891</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12040891</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Klijn</surname> <given-names>JG</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Sieuwerts</surname> <given-names>AM</given-names></name><name><surname>Look</surname> <given-names>MP</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Talantov</surname> <given-names>D</given-names></name><name><surname>Timmermans</surname> <given-names>M</given-names></name><name><surname>Meijer-van Gelder</surname> <given-names>ME</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Jatkoe</surname> <given-names>T</given-names></name><name><surname>Berns</surname> <given-names>EM</given-names></name><name><surname>Atkins</surname> <given-names>D</given-names></name><name><surname>Foekens</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer</article-title><source>The Lancet</source><volume>365</volume><fpage>671</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)17947-1</pub-id><pub-id pub-id-type="pmid">15721472</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Ghishan</surname> <given-names>FK</given-names></name><name><surname>Kiela</surname> <given-names>PR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SLC9 gene family: function, expression, and regulation</article-title><source>Comprehensive Physiology</source><volume>8</volume><fpage>555</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1002/cphy.c170027</pub-id><pub-id pub-id-type="pmid">29687889</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>NY</given-names></name><name><surname>Iftimi</surname> <given-names>A</given-names></name><name><surname>Yau</surname> <given-names>C</given-names></name><name><surname>Tobin</surname> <given-names>NP</given-names></name><name><surname>van 't Veer</surname> <given-names>L</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Benz</surname> <given-names>CC</given-names></name><name><surname>Nordenskjöld</surname> <given-names>B</given-names></name><name><surname>Fornander</surname> <given-names>T</given-names></name><name><surname>Stål</surname> <given-names>O</given-names></name><name><surname>Czene</surname> <given-names>K</given-names></name><name><surname>Esserman</surname> <given-names>LJ</given-names></name><name><surname>Lindström</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal A or luminal B breast cancer</article-title><source>JAMA Oncology</source><volume>5</volume><fpage>1304</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.1856</pub-id><pub-id pub-id-type="pmid">31393518</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeymer</surname> <given-names>U</given-names></name><name><surname>Suryapranata</surname> <given-names>H</given-names></name><name><surname>Monassier</surname> <given-names>JP</given-names></name><name><surname>Opolski</surname> <given-names>G</given-names></name><name><surname>Davies</surname> <given-names>J</given-names></name><name><surname>Rasmanis</surname> <given-names>G</given-names></name><name><surname>Linssen</surname> <given-names>G</given-names></name><name><surname>Tebbe</surname> <given-names>U</given-names></name><name><surname>Schröder</surname> <given-names>R</given-names></name><name><surname>Tiemann</surname> <given-names>R</given-names></name><name><surname>Machnig</surname> <given-names>T</given-names></name><name><surname>Neuhaus</surname> <given-names>KL</given-names></name><collab>ESCAMI Investigators</collab></person-group><year iso-8601-date="2001">2001</year><article-title>The Na<sup>+</sup>/H<sup>+</sup> exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial</article-title><source>Journal of the American College of Cardiology</source><volume>38</volume><fpage>1644</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(01)01608-4</pub-id><pub-id pub-id-type="pmid">11704395</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68447.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Liu</surname><given-names>Caigang</given-names> </name><role>Reviewer</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Dysregulated acid-base microenvironment has been revealed to be associated with several adverse outcomes, such as drug resistance and enhanced aggression. In this research a large-scale cohort comprised of patient-derived organoids were employed mimicking exactly the condition under clinical setting to observe effect of dysregulated acid-base transporter on clinical parameters and survival. This work provides potential novel therapeutic avenue through targeting acid-base transporter regulating pH.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Caigang Liu as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Maureen Murphy as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Most of the conclusions could be well supported by clinical data statistics. However, there still exist some concerns expected to be explained, especially, detailed mechanism or therapeutic strategies description regarding pH dysregulation are deficient.</p><p>2) There are several contradictory and confusing conclusions in the manuscript remaining to be discussed. It would be better to reorganize the manuscript in a clearer and more convincing manner to present the data in the study.</p><p><italic>Reviewer #1:</italic></p><p>The authors launched an observational study on 110 breast cancer organoids, measured the cancer and normal cell net acid extrusion capacity to correlate different clinicopathological parameters with intracellular pH regulator (NHE1 and NBCn1) level, and unravel the relationship between them and tumor proliferation, lymph node metastasis together with the impact of cotransporter mRNA on patient's survival, thus highlighting the role of pH regulator in malignancy. This study was performed on a large-scale cohort based on tissue samples to comprehensively reflect the heterogeneity setting. However, there lacks detailed mechanism or therapeutic strategies description regarding pH dysregulation. The data has been sufficient to hold back the views proposed and the results will provide better understanding for the role of dysregulated pH in cancer progression and help future studies regarding targeting pH regulator in managing cancer.</p><p>1. In Figure 9 and 10, SLC9A1 and SLC4A7 mRNA level was analyzed for their correlation with survival outcome, it would be better to supplement survival analysis regarding the expression of SLC9A1 and SLC4A7 protein based on your study cohort.</p><p>2. Please specify the reasons for ER and Ki-67 cut-off value setting and include them in Method or insert supporting reference literature.</p><p>3. It is described in lines 320-321 that the protein expression level of NHE1 and NBCn1 was not significantly influenced by estrogen receptor status. And it is described in lines 333-335 that the protein expression levels of NHE1 as well as NBCn1 were elevated in breast carcinomas with HER2 overexpression or gene amplification both before and after adjustment for other clinicopathological characteristics. But the survival figures of Figure 9, 10 indicated that 'For patients with HER2-enriched breast cancer, we saw no association of SLC4A7 or SLC9A1 mRNA expression with survival; The high overall SLC4A7 expression level in Luminal A breast cancer suggests a prominent role of NBCn1 in this breast cancer molecular subtype. And patients with high SLC9A1 mRNA expression suffering from Luminal A breast cancer showed significantly improved survival (hazard ratio 0.552) compared to patients with low SLC9A1 mRNA expression'. The conclusions seem to be contradictory, please explain this.</p><p>4. In lines 75-81: 'In human and murine breast cancer tissue analyzed without stratification by molecular subtype, Na+, HCO<sub>3</sub><sup>-</sup> cotransport activity is elevated and protein expression of the NBCn1 (SLC4A7) and MCT1 (SLC16A1) and MCT4 (SLC16A3) are upregulated compared to normal breast tissue. Protein expression of the NHE1 (SLC9A1) is either unchanged or moderately upregulated when breast cancer tissue as one unstratified group is compared to normal breast tissue.' However, worse prognosis was observed in patients suffering from Luminal A or Basal-like/triple-negative breast cancer with high SLC4A7 and/or low SLC9A1 mRNA expression. The expression level of NHE1 (SLC9A1) and the prognostic data are conflicting, please discuss it in detail.</p><p>5. The authors found that the expressions of NBCn1 and NHE1 were related to lymph node metastasis and cancer cell proliferation. However, lymph node metastasis and cancer cell proliferation are both key factors predicting worse prognosis. The existing data cannot indicate whether intratumor PH directly affects the patient's prognosis, or indirectly affects the prognosis through lymph nodes metastasis or cancer cell proliferation. Please add survival charts of patients in different subgroups to illustrate it.</p><p>6. The authors separately verified the effects of NBCn1 (SLC4A7), MCT1 (SLC16A1), MCT4 (SLC16A3) and NHE1 (SLC9A1) on the prognosis of patients, but whether there exist synergistic or antagonistic effect among the four genes, or whether there is mutual regulation relationship should be addressed.</p><p>7. This manuscript requires a more comprehensive summary regarding previous reported role of abnormal pH in promoting cancer in Introduction, and the same about mechanism description and future interfering strategies in Discussion to help readers comprehend this field more conveniently.</p><p>8. Breast cancer organoids are mainly composed of cytokeratin 19-positive epithelial cells while the authors only provide the microscopic pictures. It would be better to provide immunofluorescence or IHC staining pictures of cytokeratin 19-positive epithelial cells.</p><p>9. Several references date 20 years ago, new references supporting the authors' findings would strengthen the hypothesis. Meanwhile, please arrange it in accordance with the reference format required by <italic>eLife</italic>.</p><p><italic>Reviewer #2:</italic></p><p>In this extensive study, authors have shown that Na+,HCO<sub>3</sub><sup>-</sup> cotransport and Na+/H<sup>+</sup>-exchange transporters predominantly mediate overall cellular acid extrusion in breast cancer microenvironment. In addition, authors demonstrate that higher activity of Na+,HCO<sub>3</sub><sup>-</sup>-cotransport correlates with increased growth and lymph node metastasis of breast cancer. The mechanistic insights gained from the study will help in the development of therapeutic strategies for breast cancers. The strengths of this study include the use of organoid culture system, and detailed cellular acid-base homeostasis analyses in an extensive cohort of breast cancer patients. Overall, this study is of interest to the peers working in the breast cancer field.</p><p>1. It would be interesting if the authors have used genetic knockdown or specific inhibitors against NBCn1 and NHE1 in breast cancer organoids to avoid the redundant functions of other ion exchangers.</p><p>2. Did the authors analyze the expression of angiogenic markers such as CD31 or CD34 in the patient samples?</p><p>3. For the ease of readers, in Figure 1B, authors should also highlight the observations on expression and correlation of NBCn1 and NHE1 with overall survival in different breast cancer subtypes.</p><p>4. Authors should discuss the possible limitations of their study in the Discussion part of the manuscript.</p><p>5. Please correct the spelling of Maier to Kaplan-Meier in methods.</p><p>6. In Figure 1 E, authors should use only one asterisk to show the statistical significance between the groups.</p><p><italic>Reviewer #3:</italic></p><p>Nicolai J. Toft et al. investigated the feature of acid-base metabolism in breast cancer tissue from several aspects, revealing the underlying mechanism of pH regulation according to the heterogeneity. Moreover, the acid-base transport and intracellular pH state were proved capable of predicting the proliferation ability and lymph node metastasis risk of breast cancer, and were associated with the survival in specific breast cancer subtypes. The conclusions of this paper are mostly well supported by data. However, it would have been clearer and more convincing to present the clinical significance combining all data in this study, especially in a more direct way (using tables or graphs).</p><p>1. An exposition for combined analysis of the results in figure 1-6 and figure 7-8 is expected to let the readers better understand the clinical significance (like prediction for proliferation and lymph node metastasis) of the various situations in breast cancer with different acid-base metabolism features.</p><p>2. There are some questions of how to select different indicators to evaluate the prognosis tendency. For example, data in figure 5E-F and 6E-F showed that Her2 receptor increased the expression of both NBCn1 and NHE1, which exert opposite predictive function in lymph node metastasis according to the data in figure 8G. In this condition, how to evaluate the risk of metastasis? What is the clinical significance of the data on Her2-enriched subtype?</p><p>3. How to confirm the statistical significance of the difference in the figures showing &quot;traces of NH<sup>+</sup>4-prepulse-induced pHi dynamics&quot; (like figure 2A-B)? Meanwhile, the p value is better to be marked in the figures.</p><p>4. The standard to define estrogen receptor-negative breast cancer and estrogen receptor-positive breast cancer should be pointed out. The results in figure 4 is confusing.</p><p>5. The information in figure 10A and 10F showed that the mRNA of SLC4A7, which encodes protein NBCn1, expressed in a very low level and could not predict the survival prognosis in HER2-riched breast cancer subtype. However, in figure 5F and figure 6F, the data indicated that HER2 expression level was positively associated with higher NBCn1 frequency. So, a further explanation is needed for the contradiction of these data and their clinical significance.</p><p>6. The authors should add more biological and molecular experiments to better support the conclusions.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68447.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Most of the conclusions could be well supported by clinical data statistics. However, there still exist some concerns expected to be explained, especially, detailed mechanism or therapeutic strategies description regarding pH dysregulation are deficient.</p></disp-quote><p>We have now very substantially expanded the introduction (l. 82-99), results (l. 380-387), and discussion (l. 452-469 and 486-565) sections in order to better explain how our findings relate to molecular mechanisms of breast carcinogenesis and further discuss the prognostic and possible therapeutic impact of pH dysregulation. Please also see the responses to the individual reviewer comments below.</p><disp-quote content-type="editor-comment"><p>2) There are several contradictory and confusing conclusions in the manuscript remaining to be discussed. It would be better to reorganize the manuscript in a clearer and more convincing manner to present the data in the study.</p></disp-quote><p>To better convey the methodological approach and conclusions of the study and avoid confusion, we have now improved the illustration in Figure 1B and included additional schematic illustrations as a new Figure 11.</p><p>Additionally, we have reorganized the supplementary material as figure supplements linked up to the regular figures in order to create a clearer structure.</p><p>We have also expanded the discussion very substantially (l. 452-469 and 500-565). Particularly, we have added more background and explanations in the areas highlighted as confusing or contradictory by the reviewers. With the included additional information, we hope the editors and reviewers agree that the findings and conclusions of the manuscript are now more convincingly presented.</p><p>For more details, see the responses to the individual reviewer comments below.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:The authors launched an observational study on 110 breast cancer organoids, measured the cancer and normal cell net acid extrusion capacity to correlate different clinicopathological parameters with intracellular pH regulator (NHE1 and NBCn1) level, and unravel the relationship between them and tumor proliferation, lymph node metastasis together with the impact of cotransporter mRNA on patient's survival, thus highlighting the role of pH regulator in malignancy. This study was performed on a large-scale cohort based on tissue samples to comprehensively reflect the heterogeneity setting. However, there lacks detailed mechanism or therapeutic strategies description regarding pH dysregulation. The data has been sufficient to hold back the views proposed and the results will provide better understanding for the role of dysregulated pH in cancer progression and help future studies regarding targeting pH regulator in managing cancer.</p><p>1. In Figure 9 and 10, SLC9A1 and SLC4A7 mRNA level was analyzed for their correlation with survival outcome, it would be better to supplement survival analysis regarding the expression of SLC9A1 and SLC4A7 protein based on your study cohort.</p></disp-quote><p>We appreciate this suggestion. However, even though our cohort used for protein expression analyses and pH measurements – to our knowledge – is the largest existing with functional data on acid-base regulation for any type of human cancer, at this duration (2-5 years) of follow-up, it is not large enough for survival outcome analyses. The number of fatalities is too low to provide the statistical strength needed, and we have now included a comment regarding this limitation in the discussion (l. 540-546).</p><disp-quote content-type="editor-comment"><p>2. Please specify the reasons for ER and Ki-67 cut-off value setting and include them in Method or insert supporting reference literature.</p></disp-quote><p>This is an important point, which we now address on l. 651-661 and 206-212 of the revised manuscript:</p><p>Regarding ER (l. 652-656 and 206-212): “We observed a clear distinction between one group of patients with very high estrogen receptor expression (≥90% positive cells) and another group of patients with low estrogen receptor expression (≤15% positive cells) in the breast tumors. […] The absence of intermediate expression levels provided a clear and obvious cut-off value for separation between the two groups.”</p><p>Regarding Ki67 (l. 656-661): “As previously noted by others (reference 74), Ki67 expression displays a continuous distribution with no clear separation between groups of high and low expression. The median Ki67 index in our study cohort was 20%; and we therefore followed the guidelines of the 2015 St Gallen International Expert Consensus (reference 74) that in a similar population recommend a cut-off setting of 30% for identification of patients with a clearly high Ki67 index.”</p><disp-quote content-type="editor-comment"><p>3. It is described in lines 320-321 that the protein expression level of NHE1 and NBCn1 was not significantly influenced by estrogen receptor status. And it is described in lines 333-335 that the protein expression levels of NHE1 as well as NBCn1 were elevated in breast carcinomas with HER2 overexpression or gene amplification both before and after adjustment for other clinicopathological characteristics. But the survival figures of Figure 9, 10 indicated that 'For patients with HER2-enriched breast cancer, we saw no association of SLC4A7 or SLC9A1 mRNA expression with survival; The high overall SLC4A7 expression level in Luminal A breast cancer suggests a prominent role of NBCn1 in this breast cancer molecular subtype. And patients with high SLC9A1 mRNA expression suffering from Luminal A breast cancer showed significantly improved survival (hazard ratio 0.552) compared to patients with low SLC9A1 mRNA expression'. The conclusions seem to be contradictory, please explain this.</p></disp-quote><p>The point raised by the reviewer is important and underscores that there is not always straightforward proportionality between mRNA, protein, and function. This is particularly important, when making comparisons across molecular subtypes or clinicopathological characteristics driven by distinct carcinogenic mechanisms. The relationship between mRNA, protein, and function is likely much simpler when compared between individuals within the same molecular subtype; and therefore, we focus primarily on survival analyses performed following molecular subtype stratification (Figure 9, 10 and Figure 10—figure supplement 1 and 2). We now discuss this point on l. 317-324 of the revised manuscript.</p><p>The impact of estrogen and HER2 receptors on protein expression is described in Figure 4-6, and we have now included additional analyses to evaluate how <italic>ESR1</italic>, <italic>PGR</italic>, and <italic>ERBB2</italic> expression affects <italic>SLC4A7</italic> and <italic>SLC9A1</italic> mRNA levels (Figure 9-Source Data 1 and Figure 10-Source Data 1). The lower <italic>SLC4A7</italic> mRNA but higher NBCn1 protein level in HER2-enriched breast cancer imply that the HER2-dependent regulation occurs at post-transcriptional level (i.e., by an increased translational activity or higher protein stability). This relationship between mRNA and protein expression for NBCn1 is in line with previous findings in murine breast cancer tissue induced by HER2 overexpression (reference 16), where the <italic>SLC4A7</italic> mRNA level was found low despite an elevated NBCn1 protein level. The predominant post-transcriptional regulation of NBCn1 expression by HER2 complicates the interpretation of the corresponding survival analysis (Figure 10F), and we have now included a comment regarding this point in the manuscript (l. 496-506).</p><p>The high <italic>SLC4A7</italic> mRNA level in Luminal A breast cancer is consistent with a prominent regulation of NBCn1 expression at transcriptional level in this molecular subtype; and in congruence, the <italic>SLC4A7</italic> mRNA level carries predictive prognostic value for patients with Luminal A breast cancer (Figure 10D). We have now clarified and expanded this point on l. 346-351 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4. In lines 75-81：'In human and murine breast cancer tissue analyzed without stratification by molecular subtype, Na<sup>+</sup>, HCO<sub>3</sub><sup>-</sup> cotransport activity is elevated and protein expression of the NBCn1 (SLC4A7) and MCT1 (SLC16A1) and MCT4 (SLC16A3) are upregulated compared to normal breast tissue. Protein expression of the NHE1 (SLC9A1) is either unchanged or moderately upregulated when breast cancer tissue as one unstratified group is compared to normal breast tissue.' However, worse prognosis was observed in patients suffering from Luminal A or Basal-like/triple-negative breast cancer with high SLC4A7 and/or low SLC9A1 mRNA expression. The expression level of NHE1 (SLC9A1) and the prognostic data are conflicting, please discuss it in detail.</p></disp-quote><p>We have now included a much more detailed discussion of NHE1 expression in breast cancer tissue on l. 452-469 of the revised manuscript. Our data establish NHE1 as a metastasis suppressor gene in human breast cancer. Although the spatio-temporal relationships for NHE1 expression need further examination in future studies, it is not unusual that metastasis-suppressor genes are upregulated during early cancer development but downregulated during cancer progression thereby promoting cancer cell metastasis to distant regions (references 49 and 50). We have now expanded the discussion of how NHE1 expression is influenced during breast carcinogenesis and included the existing knowledge regarding NHE1 expression changes during breast cancer progression (l. 452-465). With this additional information, we hope the reviewer agrees that the conclusions based on expression, function, and survival are clearer and more consistent.</p><p>We also now emphasize (l. 465-469) that our findings are in accordance with previous studies based on the human MCF7 cancer cell line where NHE1 is upregulated in response to HER2 overexpression (reference 51) but inhibits cell migration (reference 38).</p><disp-quote content-type="editor-comment"><p>5. The authors found that the expressions of NBCn1 and NHE1 were related to lymph node metastasis and cancer cell proliferation. However, lymph node metastasis and cancer cell proliferation are both key factors predicting worse prognosis. The existing data cannot indicate whether intratumor pH directly affects the patient's prognosis, or indirectly affects the prognosis through lymph nodes metastasis or cancer cell proliferation. Please add survival charts of patients in different subgroups to illustrate it.</p></disp-quote><p>We have now included a much more detailed discussion of NHE1 expression in breast cancer tissue on l. 452-469 of the revised manuscript. Our data establish NHE1 as a metastasis suppressor gene in human breast cancer. Although the spatio-temporal relationships for NHE1 expression need further examination in future studies, it is not unusual that metastasis-suppressor genes are upregulated during early cancer development but downregulated during cancer progression thereby promoting cancer cell metastasis to distant regions (references 49 and 50). We have now expanded the discussion of how NHE1 expression is influenced during breast carcinogenesis and included the existing knowledge regarding NHE1 expression changes during breast cancer progression (l. 452-465). With this additional information, we hope the reviewer agrees that the conclusions based on expression, function, and survival are clearer and more consistent.</p><p>We also now emphasize (l. 465-469) that our findings are in accordance with previous studies based on the human MCF7 cancer cell line where NHE1 is upregulated in response to HER2 overexpression (reference 51) but inhibits cell migration (reference 38).</p><disp-quote content-type="editor-comment"><p>6. The authors separately verified the effects of NBCn1 (SLC4A7), MCT1 (SLC16A1), MCT4 (SLC16A3) and NHE1 (SLC9A1) on the prognosis of patients, but whether there exist synergistic or antagonistic effect among the four genes, or whether there is mutual regulation relationship should be addressed.</p></disp-quote><p>Our meta-analysis covers data from seven different original studies. Because of variation in the genes covered by the different studies, the n-value drops drastically if only studies covering all four genes are included in a combined analysis of synergism/antagonism. Instead, as suggested by the reviewer, we now examine whether there is mutual regulation relationships between the four genes. This can be done in pair-wise correlation analyses that maintain the original high n-values. As shown in Figure 9-Source Data 1, Figure 10-Source Data 1, Figure 10—figure supplement 1-Source Data 1, and Figure 10—figure supplement 2-Source Data 1, the gene expression levels of the four acid-base transporters vary in response to differences in <italic>ERBB2</italic>, <italic>ESR1</italic>, and <italic>PGR</italic> expression – but when corrected for these effects, we find no independent correlation between the expression levels for any pair of transporters. These findings – described and discussed in the revised manuscript (l. 380-387) – support that the survival effects of the individual transporters are independent.</p><disp-quote content-type="editor-comment"><p>7. This manuscript requires a more comprehensive summary regarding previous reported role of abnormal pH in promoting cancer in Introduction, and the same about mechanism description and future interfering strategies in Discussion to help readers comprehend this field more conveniently.</p></disp-quote><p>Our meta-analysis covers data from seven different original studies. Because of variation in the genes covered by the different studies, the n-value drops drastically if only studies covering all four genes are included in a combined analysis of synergism/antagonism. Instead, as suggested by the reviewer, we now examine whether there is mutual regulation relationships between the four genes. This can be done in pair-wise correlation analyses that maintain the original high n-values. As shown in Figure 9-Source Data 1, Figure 10-Source Data 1, Figure 10—figure supplement 1-Source Data 1, and Figure 10—figure supplement 2-Source Data 1, the gene expression levels of the four acid-base transporters vary in response to differences in <italic>ERBB2</italic>, <italic>ESR1</italic>, and <italic>PGR</italic> expression – but when corrected for these effects, we find no independent correlation between the expression levels for any pair of transporters. These findings – described and discussed in the revised manuscript (l. 380-387) – support that the survival effects of the individual transporters are independent.</p><disp-quote content-type="editor-comment"><p>8. Breast cancer organoids are mainly composed of cytokeratin 19-positive epithelial cells while the authors only provide the microscopic pictures. It would be better to provide immunofluorescence or IHC staining pictures of cytokeratin 19-positive epithelial cells.</p></disp-quote><p>Our meta-analysis covers data from seven different original studies. Because of variation in the genes covered by the different studies, the n-value drops drastically if only studies covering all four genes are included in a combined analysis of synergism/antagonism. Instead, as suggested by the reviewer, we now examine whether there is mutual regulation relationships between the four genes. This can be done in pair-wise correlation analyses that maintain the original high n-values. As shown in Figure 9-Source Data 1, Figure 10-Source Data 1, Figure 10—figure supplement 1-Source Data 1, and Figure 10—figure supplement 2-Source Data 1, the gene expression levels of the four acid-base transporters vary in response to differences in <italic>ERBB2</italic>, <italic>ESR1</italic>, and <italic>PGR</italic> expression – but when corrected for these effects, we find no independent correlation between the expression levels for any pair of transporters. These findings – described and discussed in the revised manuscript (l. 380-387) – support that the survival effects of the individual transporters are independent.</p><disp-quote content-type="editor-comment"><p>9. Several references date 20 years ago, new references supporting the authors' findings would strengthen the hypothesis. Meanwhile, please arrange it in accordance with the reference format required by eLife.</p></disp-quote><p>We have now included additional, newer references. The references dating back more than 20 years now comprise less than 12% of the total number of references and are restricted to seminal papers that lay the theoretical or technical groundwork for the research field.</p><p>Our impression – based on the instructions to authors – was that no special reference format is required by <italic>eLife</italic>. We apologize if we have misunderstood this point and now use a reference format that specifies all authors on each paper. We would appreciate further instructions if a different reference format is more convenient – in which case, we will happily modify.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>In this extensive study, authors have shown that Na<sup>+</sup>,HCO<sub>3</sub><sup>-</sup> cotransport and Na<sup>+</sup>/H<sup>+</sup>-exchange transporters predominantly mediate overall cellular acid extrusion in breast cancer microenvironment. In addition, authors demonstrate that higher activity of Na+,HCO<sub>3</sub><sup>-</sup>-cotransport correlates with increased growth and lymph node metastasis of breast cancer. The mechanistic insights gained from the study will help in the development of therapeutic strategies for breast cancers. The strengths of this study include the use of organoid culture system, and detailed cellular acid-base homeostasis analyses in an extensive cohort of breast cancer patients. Overall, this study is of interest to the peers working in the breast cancer field.</p><p>1. It would be interesting if the authors have used genetic knockdown or specific inhibitors against NBCn1 and NHE1 in breast cancer organoids to avoid the redundant functions of other ion exchangers.</p></disp-quote><p>It is important to note that the current study is based on freshly isolated organoids that are studied after only the delay (hours) needed for enzymatic digestion of the human tissue biopsies. Since the half-lives of protein degradation for NBCn1 and NHE1 in MCF7 human breast cancer cells are around 76 and 48 hours (reference 67), respectively, genetic knockdown techniques would not be possible within the time available. This is now described on l. 551-558 of the revised manuscript. We apologize if the freshly isolated organoids used in this manuscript and their difference from organoid cultures used in other studies were inadequately described. The organoids in our studies were investigated directly after enzymatic isolation without tissue culture because it is well known that culture processes dramatically influence acid-base transporter expression and function. Had the tissue been cultured, it is very likely that it would no longer resemble the human clinical condition. To further emphasize this important point, we have now expanded Figure 1B to include an ultra-brief illustration of the methodological approach and expanded the description on l. 602-603, 125-127, and 551-554 of the revised manuscript.</p><p>Regarding specific inhibitors, no such compounds currently exist for NBCn1, which we now mention on l. 558-559 of the revised manuscript. We have previously shown that the Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup>-cotransport in human breast cancer tissue has low sensitivity to 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid (DIDS), which is a pharmacological characteristic of NBCn1 compared to other Na<sup>+</sup>,HCO<sub>3</sub><sup>–</sup>-cotransporters. A comment and reference to this information has been included on l. 559-565 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. Did the authors analyze the expression of angiogenic markers such as CD31 or CD34 in the patient samples?</p></disp-quote><p>For our cohort evaluated with pH dynamics and protein expression levels for NBCn1 and NHE1, we did not analyze the expression of angiogenic markers. In addition to the protein expression analyses for NBCn1 and NHE1, the pathological information stems from the standard diagnostic pathology evaluation, which did not include CD31/PECAM or CD34. However, to accommodate the request from the reviewer, we have now assessed how CD31 and CD34 mRNA expression relates to the different breast cancer molecular subtypes evaluated in the meta-analysis. These data are now included in Figure 9—figure supplement 1 and mentioned on l. 331-333 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>3. For the ease of readers, in Figure 1B, authors should also highlight the observations on expression and correlation of NBCn1 and NHE1 with overall survival in different breast cancer subtypes.</p></disp-quote><p>This is a point well taken. Instead of expanding Figure 1B – which has already been expanded with methodological details, see point 1 above – we have included new summary schematics of our conclusions regarding NHE1 and NBCn1 in a new Figure 11 in order to best maintain the natural progression of the manuscript.</p><disp-quote content-type="editor-comment"><p>4. Authors should discuss the possible limitations of their study in the Discussion part of the manuscript.</p></disp-quote><p>We now discuss limitations of the study on l. 540-550 of the revised manuscript. These include considerations regarding n-values and follow-up time in our cohort. We also discussion that the sizes of individual subgroups are determined by the natural incidence of the various clinicopathological characteristics, which results in a less balanced distribution for some breast cancer characteristics.</p><p>On l. 551-565, we also emphasize that the current approach based on freshly isolated organoids provides the closest possible evaluation of in vivo characteristics under conditions where experimental buffer compositions can be modified and controlled. In order to study detailed molecular mechanisms and their influence on the cellular biology, future studies in model systems will be important.</p><disp-quote content-type="editor-comment"><p>5. Please correct the spelling of Maier to Kaplan-Meier in methods.</p></disp-quote><p>Thank you for pointing this out – corrected twice in the methods section (l. 678 and 700).</p><disp-quote content-type="editor-comment"><p>6. In Figure 1 E, authors should use only one asterisk to show the statistical significance between the groups.</p></disp-quote><p>The asterisks were meant to indicate the statistical difference relating to two different comparisons between the cancer tissue and the normal breast tissue: one in the presence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>, the other in the absence of CO<sub>2</sub>/HCO<sub>3</sub><sup>–</sup>. We apologize if this was not clear and have now changed the layout of the figure panel to avoid confusion.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>Nicolai J. Toft et al. investigated the feature of acid-base metabolism in breast cancer tissue from several aspects, revealing the underlying mechanism of pH regulation according to the heterogeneity. Moreover, the acid-base transport and intracellular pH state were proved capable of predicting the proliferation ability and lymph node metastasis risk of breast cancer, and were associated with the survival in specific breast cancer subtypes. The conclusions of this paper are mostly well supported by data. However, it would have been clearer and more convincing to present the clinical significance combining all data in this study, especially in a more direct way (using tables or graphs).</p><p>1. An exposition for combined analysis of the results in figure 1-6 and figure 7-8 is expected to let the readers better understand the clinical significance (like prediction for proliferation and lymph node metastasis) of the various situations in breast cancer with different acid-base metabolism features.</p></disp-quote><p>As suggested, we have now markedly expanded the explanation and discussion of the analyses on l. 452-469, and 507-565 of the revised manuscript. The additional discussion highlights the clinical significance and several pathological characteristics in breast cancer that based on our findings are likely to be at least partly due to the acid-base features of the individual molecular subtypes.</p><disp-quote content-type="editor-comment"><p>2. There are some questions of how to select different indicators to evaluate the prognosis tendency. For example, data in figure 5E-F and 6E-F showed that Her2 receptor increased the expression of both NBCn1 and NHE1, which exert opposite predictive function in lymph node metastasis according to the data in figure 8G. In this condition, how to evaluate the risk of metastasis? What is the clinical significance of the data on Her2-enriched subtype?</p></disp-quote><p>This is an excellent point, which we now discuss in greater detail on l. 507-514 of the revised manuscript. The dual effect of HER2 on expression of NBCn1 and NHE1 is intriguing as it suggests that more detailed analyses (e.g., relative regulation of NBCn1 vs NHE1) may provide more accurate predictive value than simple evaluation of HER2 overexpression/gene amplification. Our findings furthermore suggest that selective targeting of individual HER2-activated downstream signaling pathways (including individual acid-base transporters) could optimize the current therapeutic approach based on direct HER2 inhibition.</p><disp-quote content-type="editor-comment"><p>3. How to confirm the statistical significance of the difference in the figures showing &quot;traces of NH<sub>4</sub><sup>+</sup>-prepulse-induced pH<sub>i</sub> dynamics&quot; (like figure 2A-B)? Meanwhile, the p value is better to be marked in the figures.</p></disp-quote><p>We have now included a paragraph (l. 151-155) that explains the relationship between the different panels, i.e., how data extracted from the pH<sub>i</sub> traces (like Figure 2A,B) were summarized and statistically compared in the associated panels (like Figure 2C,D and Figure 2—figure supplement 2). The statistical analyses compared the net acid extrusion capacities (Figure 2C) and steady-state pH<sub>i</sub> levels (Figure 2D) derived from the pH<sub>i</sub> traces. We include the traces in order to give the reader a better feel for the recordings underlying our analyses, which is in line with the recommendation in the <italic>eLife</italic> instructions to authors that traces should be included whenever possible.</p><disp-quote content-type="editor-comment"><p>4. The standard to define estrogen receptor-negative breast cancer and estrogen receptor-positive breast cancer should be pointed out. The results in figure 4 is confusing.</p></disp-quote><p>We apologize if the description of the nomenclature was inadequate and confusing. We have now described in detail how we distinguished between breast cancer samples with highly elevated estrogen receptor expression (ER-positive breast cancer: ≥90% ER<sup>+</sup> cells) and samples where the estrogen receptor expression was in a range similar to that previously reported for normal breast tissue (ER-normal breast cancer: ≤15% ER<sup>+</sup> cells) on l. 206-212 and 652-656 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5. The information in figure 10A and 10F showed that the mRNA of SLC4A7, which encodes protein NBCn1, expressed in a very low level and could not predict the survival prognosis in HER2-riched breast cancer subtype. However, in figure 5F and figure 6F, the data indicated that HER2 expression level was positively associated with higher NBCn1 frequency. So, a further explanation is needed for the contradiction of these data and their clinical significance.</p></disp-quote><p>This is a very good point. The lower <italic>SLC4A7</italic> mRNA but higher NBCn1 protein level in HER2-enriched breast cancer imply that the HER2-dependent regulation occurs at post-transcriptional level (i.e., by an increased translational activity or higher protein stability). This relationship between mRNA and protein expression for NBCn1 is in line with previous findings in murine breast cancer tissue induced by HER2 overexpression (reference 16), where the <italic>SLC4A7</italic> mRNA level was found low despite an elevated NBCn1 protein level. The predominant post-transcriptional regulation of NBCn1 expression by HER2 complicates the interpretation of the corresponding survival analysis (Figure 10F), and we have now included a comment regarding this point in the manuscript (l. 496-506).</p><disp-quote content-type="editor-comment"><p>6. The authors should add more biological and molecular experiments to better support the conclusions.</p></disp-quote><p>The unique strength of the current study is the clinically relevant functional data on pH dynamics from a human cohort of previously unparalleled size. The data set is unique because it so clearly links up to the human clinical condition and embraces its heterogeneity and complexity, thereby allowing us to establish relationships between pH dynamics and clinical and pathological characteristics, which has not been possible before. To establish this link convincingly, we performed the functional recordings immediately after organoid isolation from the sampled tissue biopsies in order to avoid culture-induced phenotypical changes. The short time period between tissue sampling and the functional experiments, however, makes the approach unsuited for molecular interventions as the half-lives of protein degradation is ~76 hours for NBCn1 and ~48 hours for NHE1 (reference 81). We now discuss these points in the revised manuscript (l. 551-565).</p><p>Although beyond the scope of the current study, the results from the current study has already prompted new biological and molecular investigations in our group based on murine breast cancer models that are further away from the human clinical condition but much better suited for molecular intervention. Undoubtedly, the current study will also stimulate new molecular studies from colleagues in the field.</p></body></sub-article></article>